Symbol
stringlengths 1
5
| Security
stringlengths 4
59
| Sector
stringclasses 13
values | Industry
stringclasses 132
values | URL
stringlengths 43
135
| Date
stringlengths 19
19
| RelatedStocksList
stringlengths 2
859
| Article
stringlengths 0
1.06M
| Title
stringlengths 7
254
| articleType
stringclasses 2
values | Publication
stringclasses 128
values | Author
stringclasses 729
values | Risk_Free_Rate
float64 0
0.06
| weighted_avg_-96_hrs
float64 0
1.02k
| weighted_avg_-48_hrs
float64 0
1.8k
| weighted_avg_-24_hrs
float64 0
2.08k
| weighted_avg_0_hrs
float64 0
1.11k
| weighted_avg_0.25_hrs
float64 0
1.11k
| weighted_avg_0.50_hrs
float64 0
1.11k
| weighted_avg_1_hrs
float64 0
1.11k
| weighted_avg_2_hrs
float64 0
1.05k
| weighted_avg_4_hrs
float64 0
1.05k
| weighted_avg_6_hrs
float64 0
1.05k
| weighted_avg_8_hrs
float64 0
1.72k
| weighted_avg_12_hrs
float64 0
1.76k
| weighted_avg_24_hrs
float64 0
1.8k
| weighted_avg_48_hrs
float64 0
1.05k
| weighted_avg_72_hrs
float64 0
926
| weighted_avg_96_hrs
float64 0
926
| weighted_avg_360_hrs
float64 0
1.85k
| weighted_avg_720_hrs
float64 0
1.03k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TDOC | Teladoc Health, Inc. | Health Care | Medical/Nursing Services | https://www.nasdaq.com/articles/teladoc-health-tdoc-shares-down-89-despite-q2-earnings-beat | 2024-08-04 01:32:00 | Stocks|ELV|UNH|HCA | **Teladoc Health, Inc. **’s [TDOC](https://www.nasdaq.com/market-activity/stocks/tdoc) shares lost 8.9% since it reported second-quarter 2024 results on Jul 31, despite an earnings beat. Investors might be worried about BetterHelp's substantial revenue drop, leading to a decline in its adjusted EBITDA. Moreover, the withdrawal of full-year guidance for BetterHelp and the lack of consolidated guidance for the rest of the year added to the uncertainty. Strength in the Integrated Care segment acted as a partial offset.The company incurred a second-quarter 2024 adjusted loss of 28 cents per share, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago quarter’s loss of 40 cents. Operating revenues amounted to $642.4 million, which declined 1.5% year over year. The top line missed the consensus mark by 1.1%. **Teladoc Health, Inc. Price, Consensus and EPS Surprise** [](https://www.zacks.com/stock/chart/TDOC/price-consensus-eps-surprise-chart?icid=chart-TDOC-price-consensus-eps-surprise-chart)[Teladoc Health, Inc. price-consensus-eps-surprise-chart](https://www.zacks.com/stock/chart/TDOC/price-consensus-eps-surprise-chart?icid=chart-TDOC-price-consensus-eps-surprise-chart) | [Teladoc Health, Inc. Quote](https://www.nasdaq.com/market-activity/stocks/tdoc)**Quarterly Operational Update** Revenues from access fees (which accounted for 87% of total quarterly revenues) declined 3% year over year to $559.6 million in the quarter under review. The metric missed the Zacks Consensus Estimate of $565 million.Other revenues of $82.8 million increased 8% year over year but were lower than the Zacks Consensus Estimate of $85 million. On a geographical basis, Teladoc Health generated $540.8 million in revenues from the United States, down 4% year over year, in the second quarter. U.S. revenues made up nearly 84% of total revenues. The metric missed the consensus mark of $555 million. International revenues rose 12% year over year to $101.6 million and outpaced the consensus mark of $93 million.Adjusted EBITDA climbed 24% year over year to $89.5 million. The adjusted gross margin of 70.7% deteriorated 10 basis points (bps) year over year.Total expenses increased more than one-fold year over year to $1.5 billion in the quarter, higher than our estimate of $717.3 million. The year-over-year rise resulted from higher amortization of intangible assets and a major goodwill impairment. **Segmental Update** The **Integrated Care** segment reported revenues of $377.4 million, which improved 5% year over year in the second quarter and surpassed the Zacks Consensus Estimate of $375 million as well as our estimate of $373.1 million. Adjusted EBITDA soared 69% year over year to $64 million, higher than the consensus mark of $49.2 million and our estimate of $45.9 million. Adjusted EBITDA margin of 17% improved 642 bps year over year.The** BetterHelp** segment’s revenues declined 9% year over year to $265 million and missed the Zacks Consensus Estimate of $274 million and our estimate of $274.7 million. Adjusted EBITDA of $25.45 million fell 26% year over year and missed the consensus mark of $25.47 million and our estimate of $27 million. Adjusted EBITDA margin deteriorated 209 bps year over year to 9.6% in the quarter under review. **Visits & Memberships** Total visits of Teladoc Health were 4.2 million, which slipped 11% year over year and fell short of the Zacks Consensus Estimate of 5.2 million and our estimate of 4.6 million.U.S. Integrated Care Members totaled 92.4 million as of Jun 30, 2024, which improved 8% year over year. The metric beat the consensus mark by a whisker. **Financial Update (as of Jun 30, 2024)**Teladoc Health exited the second quarter with cash and cash equivalents of $1.2 billion, which slid 3.4% from the figure in 2023-end. Total assets of $3.5 billion fell 20.5% from the 2023-end level.Debt amounted to $989.7 million, which declined 35.7% from the figure as of Dec 31, 2023. Total stockholders’ equity of $1.5 billion declined 34.8% from the 2023-end level.Net cash provided by operating activities amounted to $97.6 million in the first half of 2024, which dropped 14.6% year over year. Free cash flows were $60.9 million in the quarter under review. Capex plunged 24.1% year over year to $27.7 million. **Outlook****Third-Quarter View** Revenues in the Integrated Care segment are forecasted to witness (1)-2% year-over-year growth while the unit’s adjusted EBITDA margin is anticipated to remain within 14.5-16%. U.S. Integrated Care Members are expected to be between 92.5 and 93.5 million. **2024 View** Revenues in the Integrated Care segment are expected to witness low to mid-single-digit growth on a year-over-year basis.U.S. Integrated Care Members are expected to remain within 92.5-94 million.Adjusted EBITDA margin in the Integrated Care segment is estimated to expand in the range of 150-200 bps year over year in 2024. **Zacks Rank** Teladoc Health currently carries a Zacks Rank #3 (Hold). You can see ** [the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). ** **Other Medical Sector Releases** Of the [Medical](https://www.zacks.com/stocks/industry-rank/sector/medical-4) sector players that have reported second-quarter 2024 results so far, the bottom-line results of **UnitedHealth Group Incorporated** [UNH](https://www.nasdaq.com/market-activity/stocks/unh), **Elevance Health, Inc. ** [ELV](https://www.nasdaq.com/market-activity/stocks/elv) and **HCA Healthcare, Inc.** [HCA](https://www.nasdaq.com/market-activity/stocks/hca) beat the respective Zacks Consensus Estimate.UnitedHealth Group reported second-quarter adjusted EPS of $6.80, which beat the Zacks Consensus Estimate by 2.3%. The bottom line rose 10.7% year over year. Revenues amounted to $98.9 billion, which improved 6.4% year over year. The top line outpaced the consensus mark of $98.7 billion The medical care ratio of UnitedHealth Group deteriorated 190 bps year over year to 85.1% .UNH’s operating earnings deteriorated 2.3% year over year to $7.9 billion. The net margin deteriorated to 4.3% compared with 5.9% in the year-ago period. The health benefits business of UnitedHealth Group, UnitedHealthcare, generated revenues of $73.9 billion. The figure rose 5.3% year over year. The UnitedHealthcare business served 50.4 million people as of Jun 30, 2024, which decreased 4.6% year over year. Revenues in the Optum business line were $62.9 billion, which climbed 11.7% year over year.Elevance Health reported second-quarter adjusted earnings of $10.12 per share, which outpaced the Zacks Consensus Estimate by 1.3%. The bottom line improved 12% year over year. Operating revenues of $43.2 billion dipped 0.4% year over year. However, the top line beat the consensus mark by 0.5%. Medical membership of Elevance Health was around 45.8 million as of Jun 30, 2024, which slipped 5% year over year. Premiums decreased 3.2% year over year to $35.4 billion. Product revenues of $5.5 billion advanced 13.8% year over year.The Health Benefits segment’s operating revenues totaled $37.2 billion, which decreased 2.2% year over year. Operating gain remained almost flat year over year at $2.1 billion. The operating margin of 5.8% improved 20 bps year over year. The Carelon unit’s operating revenues amounted to $13.3 billion, which rose 10% year over year. HCA Healthcare reported second-quarter adjusted EPS of $5.50, which beat the Zacks Consensus Estimate by 10.7%. The bottom line improved 28.2% year over year. Revenues amounted to $17.5 billion, which improved 10.3% year over year. The top line outpaced the consensus mark by 2.2%. Same-facility equivalent admissions increased 5.2% year over year while same-facility admissions grew 5.8% year over year.Same-facility revenue per equivalent admission rose 4.4% year over year. Same-facility inpatient surgeries grew 2.6% year over year while same-facility outpatient surgeries declined 2.1% year over year. Additionally, same-facility emergency room visits rose 5.5% year over year and beat our growth estimate of 4.3%. Adjusted EBITDA improved 16.2% year over year to $3.6 billion. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_210_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541) [UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=UNH&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=HCA&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=TDOC&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[Elevance Health, Inc. (ELV) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=ELV&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315541/teladoc-health-tdoc-shares-down-8-9-despite-q2-earnings-beat?cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315541)[Zacks Investment Research](https://www.zacks.com/) | Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat | News | Zacks | Zacks Equity Research | 0.0552 | 9.78985 | 8.45839 | 7.94092 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.90968 | 7.87319 | 7.79219 | 7.54 | 7.12812 | 7.10158 | 7.20392 |
TRDA | Entrada Therapeutics, Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/bausch-health-bhc-q2-earnings-line-xifaxan-boosts-sales | 2024-08-04 01:38:00 | Stocks|AMRX|BHC|HALO | **Bausch Health Companies Inc.'s** [BHC](https://www.nasdaq.com/market-activity/stocks/bhc) reported second-quarter adjusted earnings per share of 89 cents, on par with the Zacks Consensus Estimate. The reported figure increased from 81 cents in the year-ago quarter due to higher revenues.Total revenues of $2.4 billion were up 11% year over year. The top line also beat the Zacks Consensus Estimate of $2.3 billion. Excluding the impact of foreign exchange of $25 million, acquisitions of $104 million, and divestitures and discontinuations of $14 million, revenues increased 8% organically.BHC’s shares have lost 24% year to date against the [industry](https://www.zacks.com/stocks/industry-rank/industry/medical-generic-drugs-107)’s growth of 14.8%.[Zacks Investment Research](https://staticx-tuner.zacks.com/images/articles/charts/eb/73231.jpg?v=1242004577) Image Source: Zacks Investment Research** Quarter in Detail** The company reports revenues through five segments — Salix, International, Diversified Products, Solta Medical and Bausch + Lomb.Salix revenues totaled $558 million, flat year over year. Within this segment, Xifaxan revenues were up 10%, led by strong growth in underlying demand. The growth in Xifaxan was offset by a decline in Relistor and Trulance revenues. Xifaxan 550 mg tablets are indicated for the reduction in the risk of overt hepatic encephalopathy (HE) recurrence and the treatment of IBS-D in adults.Salix revenues missed the Zacks Consensus Estimate of $560 million but matched our model estimate of $557.7 million.International revenues totaled $276 million, up 7% year over year, led by double-digit organic growth in Canada and mid-single-digit growth in Latin America. The figure beat both the Zacks Consensus Estimate and our model estimate of $274 million. Revenues increased 6% organically.Diversified Product revenues amounted to $251 million, up 10% from the year-ago quarter’s level due to an increase in neurology and dermatology sales. Dermatology revenues grew 21% as BHC focused on returning this business to consistent growth.Cabtreo (the first and only FDA-approved fixed-dose, triple-combination topical treatment for acne vulgaris) was launched in January and has performed in line with the company’s expectations. Neurology posted an 11% year-over-year increase as the business benefited from competitor supply disruptions. Sales from the Dentistry business were flat year over year, and management expects this business to grow. Generics business was down due to competitive pressure. Diversified Product revenues beat the Zacks Consensus Estimate of $250 million and our model estimate of $226 million.Solta Medical reported revenues of $102 million, up 16% year over year. The figure beat the Zacks Consensus Estimate of $100 million but missed our model estimate of $103 million. Revenues were up 19% organically, primarily driven by strong results in Asia Pacific, especially China.Revenues from Bausch + Lomb totaled $1.21 billion, up 17% year over year. The figure beat the Zacks Consensus Estimate of $1.17 billion and our model estimate of $1.15 billion. Bausch + Lomb’s revenues increased 10% organically on a year-over-year basis, driven by growth across all business units. **Pipeline Development** The phase II study on amiselimod, a new oral S1P receptor modulator that targets the treatment of mild to moderate ulcerative colitis (UC), completed enrollment. BHC also submitted a draft protocol to the FDA for a phase III study for moderate to severe UC patients and plans to meet the EMEA authorities in the second half of the year. BHC is also advancing plans for a phase II study on amiselimod for Crohn's disease.The phase III studies in the RED-C program on rifaximin for the prevention and delay of the first episode of hepatic encephalopathy are in the treatment phase. The submission for next-generation Fraxel, a fractionated laser device for skin resurfacing, has been completed in the United States, with an approval expected sometime in the second half of the year.The company’s program for Clear and Brilliant Touch, a fractionated laser device for skin rejuvenation, is also advancing, with regulatory submissions planned for Europe, Canada and Asia Pacific markets in 2024. **Other Updates** In April 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. District Court for the District of Delaware in the Norwich matter. In its ruling, the Federal Court denied Norwich Pharmaceuticals’ motion for modification of the court’s final order. As a result, the FDA cannot approve Norwich’s abbreviated new drug application (ANDA) for Xifaxan (rifaximin) 550 mg until October 2029.In June 2024, BHC filed a second patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich. The lawsuit was filed in connection with a Notice of Paragraph IV Certification received from Norwich related to an amended ANDA requesting approval to market a generic version of Xifaxan 550 mg for the treatment of IBS-D.During the second quarter, BHC also filed a lawsuit against **Amneal Pharmaceuticals** [AMRX](https://www.nasdaq.com/market-activity/stocks/amrx) and its subsidiaries. The lawsuit was filed on the heels of the Notice of Paragraph IV Certification, stating that Amneal submitted an ANDA to the FDA seeking approval to market a generic version of Xifaxan 550 mg tablets. **2024 Guidance Raised** BHC now expects revenues to be in the range of $9.4-$9.65 billion (previous estimate: $9.3-$9.55 billion). The rise was due to an increase in the guidance of Bausch + Lomb. Excluding Bausch + Lomb, revenues are anticipated to be in the band of $4.7-$4.850 billion (unchanged). **Bausch Health Cos Inc. Price, Consensus and EPS Surprise** [](https://www.zacks.com/stock/chart/BHC/price-consensus-eps-surprise-chart?icid=chart-BHC-price-consensus-eps-surprise-chart)[Bausch Health Cos Inc. price-consensus-eps-surprise-chart](https://www.zacks.com/stock/chart/BHC/price-consensus-eps-surprise-chart?icid=chart-BHC-price-consensus-eps-surprise-chart) | [Bausch Health Cos Inc. Quote](https://www.nasdaq.com/market-activity/stocks/bhc)**Our Take** Bausch's second-quarter results were encouraging as growth in revenues drove earnings. The Salix business maintained its momentum on the back of Xifaxan, which witnessed strong growth in underlying demand.Last month, BHC’s shares tanked on rumors that the company is heading toward bankruptcy. These rumors were subsequently squashed by the company. **Zacks Rank and Stocks to Consider** Bausch currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector are **Entrada Therapeutics** [TRDA](https://www.nasdaq.com/market-activity/stocks/trda) and **Halozyme Therapeutics** [HALO](https://www.nasdaq.com/market-activity/stocks/halo), each sporting a Zacks Rank #1 (Strong Buy) at present. You can see ** [the complete list of today’s Zacks #1 Rank stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link)**.In the past 60 days, estimates for Entrada Therapeutics’ 2024 loss per share have improved from 14 cents to 13 cents, and the same for 2025 have improved from $3.44 to $3.21. Year to date, shares of Entrada Therapeutics have risen 5.7%.In the past 60 days, the Zacks Consensus Estimate for Halozyme Therapeutics’ earnings has risen from $3.69 per share to $3.90. For 2025, earnings estimates have increased from $4.50 to $4.81 in the past 60 days. Year to date, shares of HALO have surged 48.9%.Earnings of Halozyme beat estimates in three of the trailing four quarters and matched the same in one, delivering an average surprise of 9.40%. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_210_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=HALO&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[Bausch Health Cos Inc. (BHC) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BHC&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=AMRX&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=TRDA&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315552/bausch-health-bhc-q2-earnings-in-line-xifaxan-boosts-sales?cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315552)[Zacks Investment Research](https://www.zacks.com/) | Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales | News | Zacks | Zacks Equity Research | 0.0552 | 17.0013 | 15.8871 | 14.7385 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.3041 | 14.2685 | 14.4665 | 14.8174 | 14.0512 | 16.5712 | 17.9666 |
TXO | TXO Partners L.P. | Energy | Oil & Gas Production | https://www.nasdaq.com/articles/will-txo-partners-lp-txo-beat-estimates-again-its-next-earnings-report | 2024-08-04 01:56:00 | Stocks | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider TXO Partners LP (TXO). This company, which is in the Zacks Energy and Pipeline - Master Limited Partnerships industry, shows potential for another earnings beat.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 157.21%, on average, in the last two quarters. For the last reported quarter, TXO Partners LP came out with earnings of $0.33 per share versus the Zacks Consensus Estimate of $0.24 per share, representing a surprise of 37.50%. For the previous quarter, the company was expected to post earnings of $0.26 per share and it actually produced earnings of $0.98 per share, delivering a surprise of 276.92%.With this earnings history in mind, recent estimates have been moving higher for TXO Partners LP. In fact, the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises). In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates [right before an earnings release](https://www.zacks.com/stock/research/TXO/earnings-calendar) have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.TXO Partners LP currently has an Earnings ESP of +13.51%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #1 (Strong Buy) indicates that another beat is possibly around the corner. When the Earnings ESP comes up negative, investors should note that this will reduce the predictive power of the metric. But, a negative value is not indicative of a stock's earnings miss.Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_516_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_7-2315495)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_516&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_7-2315495)[TXO Partners LP (TXO) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=TXO&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_516&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_7-2315495)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315495/will-txo-partners-lp-txo-beat-estimates-again-in-its-next-earnings-report?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_7-2315495)[Zacks Investment Research](https://www.zacks.com/) | Will TXO Partners LP (TXO) Beat Estimates Again in Its Next Earnings Report? | News | Zacks | Zacks Equity Research | 0.0552 | 20.3098 | 20.1879 | 19.5859 | 19.5001 | 19.4035 | 19.2508 | 19.2508 | 19.2508 | 19.2508 | 19.2508 | 19.2508 | 19.2508 | 19.2237 | 20.0686 | 19.5811 | 20.0991 | 20.6509 | 19.7494 |
HONE | HarborOne Bancorp, Inc. | Finance | Major Banks | https://www.nasdaq.com/articles/why-harborone-bancorp-hone-might-be-well-poised-surge | 2024-08-04 01:56:00 | Stocks | HarborOne Bancorp (HONE) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.Analysts' growing optimism on the earnings prospects of this bank holding company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core. The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive [externally-audited track record of outperformance](https://www.zacks.com/performance/), with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.For HarborOne Bancorp, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year. **Current-Quarter Estimate Revisions** The earnings estimate of $0.18 per share for the current quarter represents a change of -10% from the number reported a year ago.Over the last 30 days, the Zacks Consensus Estimate for HarborOne Bancorp has increased 7.58% because three estimates have moved higher compared to no negative revisions. **Current-Year Estimate Revisions** For the full year, the earnings estimate of $0.68 per share represents a change of +9.68% from the year-ago number. There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, three estimates have moved up for HarborOne Bancorp versus no negative revisions. This has pushed the consensus estimate 5.47% higher. **Favorable Zacks Rank** The promising estimate revisions have helped HarborOne Bancorp earn a Zacks Rank #2 (Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision. You can see [the complete list of today's Zacks #1 Rank (Strong Buy) stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi_1linklink).Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500. **Bottom Line** HarborOne Bancorp shares have added 18.6% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_517_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_8-2315504)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_517&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_8-2315504)[HarborOne Bancorp, Inc. (HONE) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=HONE&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_517&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_8-2315504)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315504/why-harborone-bancorp-hone-might-be-well-poised-for-a-surge?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_8-2315504)[Zacks Investment Research](https://www.zacks.com/) | Why HarborOne Bancorp (HONE) Might be Well Poised for a Surge | News | Zacks | Zacks Equity Research | 0.0552 | 13.4092 | 12.2802 | 12.45 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1544 | 12.1328 | 11.9006 | 12.0418 | 12.1302 | 12.5562 | 13.0528 |
TERN | Terns Pharmaceuticals, Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/3-biotech-stocks-could-have-investors-grinning-soon | 2024-08-04 02:00:00 | AMGN|Markets|VRTX | [InvestorPlace - Stock Market News, Stock Advice & Trading Tips](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral) Investing in [biotech stocks](https://investorplace.com/industries/healthcare/biotech/?utm_source=Nasdaq&utm_medium=referral) is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their investigational therapies fail to make it to market. The pandemic focused a lot of attention on the sector. The **SDPR S&P Biotech ETF** (NYSEARCA: [XBI](http://www.nasdaq.com/symbol/xbi)) soared 49% in 2020, outpacing the **S&P 500** and the **Nasdaq 100**. But the exchange-traded fund has faced a more difficult road since. The ETF is down 30% as investor attention was drawn to artificial intelligence.Yet biotech stocks are [making a comeback](https://investorplace.com/2024/04/these-3-biotech-stocks-are-up-269-in-2024-is-there-more-to-come/?utm_source=Nasdaq&utm_medium=referral). The biotech ETF is up 11% year-to-date and though it still trails the broad market index, the gap has been substantially narrowed.The benefit of investing in biotech stocks is that they tend to perform better in down markets. And the fact that they can develop life-altering drugs too is a benefit. Below are three biotech stocks that will leave investors smiling with the returns they produce for their portfolios. **Amgen (AMGN)** [the Amgen (AMGN) logo on a building during daylight](https://investorplace.com/wp-content/uploads/2019/11/amgn-stock-1-300x169.jpg) Source: Michael Vi / Shutterstock.comProbably no discussion of biotech stocks can be had without starting with **Amgen** (NASDAQ: [AMGN](http://www.nasdaq.com/symbol/amgn)). It is one of the [world’s largest independent biotechs](https://investorplace.com/2024/07/3-fabulous-growth-stocks-to-buy-and-hold-forever/?utm_source=Nasdaq&utm_medium=referral) with $26.9 billion in revenue last year. Sales are up 22% so far in 2024. Amgen has a massive portfolio of billion-dollar therapies led by Prolia, its treatment for osteoporosis and bone cancer. Last year it [brought in over $4 billion](https://www.sec.gov/ix?doc=/Archives/edgar/data/318154/000031815424000011/amgn-20231231.htm) in sales and it generated $1 billion worth in the first quarter. Other significant drugs include Enbrel, Otezla and Xgeva, all of which produced $2 billion or more in revenue last year.The biotech stock also has a [long and deep bench](https://www.amgenpipeline.com/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/PDF/amgen-pipeline-chart.pdf) of therapies in its pipeline that are in various phases of clinical trials.Since its IPO in 1983, Amgen has returned 135,300% to investors. A $10,000 investment back then would be worth over $13.5 million today. AMGN stock is up 15% in 2024 and is 42% higher over the last 12 months. With a dividend that yields 2.8% annually, investors will be laughing all the way to the bank by buying this biotech stock today. **Terns Pharmaceuticals (TERN)** [pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory](https://investorplace.com/wp-content/uploads/2022/08/pharmaceutical1600-300x169.png) Source: Dmitry Kalinovsky / Shutterstock.comA riskier biotech stock to buy is **Terns Pharmaceuticals** (NASDAQ: [TERN](http://www.nasdaq.com/symbol/tern)). It is a clinical-stage biopharmaceutical developing therapies to treat cancer and obesity. Its focus is on small molecule candidates, which can be administered orally and can pass through cell membranes to reach their intracellular target. Terns has two lead drugs in [early clinical trials](https://www.sec.gov/ix?doc=/Archives/edgar/data/1831363/000095017024058209/tern-20240513.htm). TERN-701 is in Phase 1 trials for the treatment of chronic myeloid leukemia (CML), a form of cancer that begins in the bone marrow. TERN-601 is also in Phase 1 trials and is for the treatment of obesity. It is an oral GLP-1 therapy targeting the same market that Ozempic and Zepound do for **Novo Nordisk**(NYSE: [NVO](http://www.nasdaq.com/symbol/nvo)) and **Eli Lilly** (NYSE: [LLY](http://www.nasdaq.com/symbol/lly)), respectively.The biotech expects to report updates on their progress in the second half of the year. A third drug in preclinical stages, TERN-501, shows significant promise in tests on mice when combined with semaglutide, the active ingredient in Ozempic and Wegovy, as well as tirzepatide, the dual receptor agonist in Lilly’s Mounjaro and Zepbound.While a high-risk investment, Terns Pharmaceuticals is also a potential takeover candidate, especially for a larger pharmaceutical wanting to jumpstart its own anti-obesity drug portfolio. **Vertex Pharmaceuticals (VRTX)** [Vertex Pharmaceuticals (VRTX) logo visible on display screen](https://investorplace.com/wp-content/uploads/2020/06/vrtx-stock-1-300x169.jpg) Source: Pavel Kapysh / Shutterstock.comAlso in the high-risk category is **Vertex Pharmaceuticals** (NASDAQ: [VRTX](http://www.nasdaq.com/symbol/vrtx)), a biotech stock laser-focused on treating cystic fibrosis (CF). While Vertex generated $9.8 billion last year from its four drugs for CF, the risk comes from being so narrowly defined. Any new entrant with a better treatment could seriously impair Vertex’s business. Yet the biotech is miles ahead of the competition, which does minimize the risk. And sales are growing, up 13% in the first quarter to $2.7 billion, which generated net profits of $1.1 billion. That is a 57% increase from the year-ago period.Of the estimated 88,000 patients with CF in North America, Europe and Australia, Vertex [treats more than two-thirds](https://investorplace.com/2023/08/got-600-here-are-3-no-brainer-stocks-you-absolutely-must-buy/?utm_source=Nasdaq&utm_medium=referral) of them.Yet the biotech is widening its lens beyond CF to expand into the rare disease drug market. Its partnership with **CRISPR Therapeutics** (NASDAQ: [CRSP](http://www.nasdaq.com/symbol/crsp)), for example, resulted in the gene-editing therapy Casgevy getting [approved for the treatment](https://investorplace.com/2024/07/the-top-3-cathie-wood-stocks-to-buy-now-summer-2024/?utm_source=Nasdaq&utm_medium=referral) of transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD).Shares of Vertex Pharmaceuticals stock is up 22% this year and stands 40% above where it was a year ago. With the dominant position in CF treatments and a potential billion-dollar blockbuster on its hands for other rare diseases, VRTX is a biotech stock worth buying.On the date of publication, Rich Duprey held a LONG position in TERN stock. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com [Publishing Guidelines](https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&utm_medium=referral). On the date of publication, the responsible editor did not have (either directly orindirectly) any positions in the securities mentioned in this article. Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L’Express, and numerous other news outlets. **More From InvestorPlace** - [Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”](https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&eid=MKT802109&utm_source=Nasdaq&utm_medium=referral) The post [3 Biotech Stocks That Could Have Investors Grinning Soon](https://investorplace.com/2024/08/3-biotech-stocks-that-could-have-investors-grinning-soon/?utm_source=Nasdaq&utm_medium=referral) appeared first on [InvestorPlace](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral). | 3 Biotech Stocks That Could Have Investors Grinning Soon | News | InvestorPlace | Rich Duprey | 0.0552 | 7.49014 | 7.66736 | 7.53589 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.18804 | 7.13487 | 7.84816 | 7.45322 | 6.70666 | 7.21782 | 7.62641 |
ESPR | Esperion Therapeutics, Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/product-demand-likely-aid-organons-ogn-q2-earnings | 2024-08-04 02:05:00 | Stocks|OGN|ILMN|MDWD | **Organon & Co.** [OGN](https://www.nasdaq.com/market-activity/stocks/ogn) is scheduled to report [second-quarter 2024 results](https://www.zacks.com/stock/research/OGN/earnings-calendar?icid=quote-detailed_estimates-quote_nav_tracking-zcom-left_subnav_quote_navbar-earnings_dates_announcements) on Aug 6, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $1.22 surpassed the Zacks Consensus Estimate by 25.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 13.6%, on average. Let’s check out the factors that have shaped OGN’s performance prior to this announcement. **Factors to Note****Women’s Health** In first-quarter 2024, Organon's Women’s Health segment recorded a solid uptick in its revenues, primarily driven by the strength of Nexplanon (etonogestrel implant). This, in turn, was driven by the favorable year-over-year comparison of customer purchasing patterns associated with the timing of U.S. list-price adjustments, along with favorable price and discount rates in the United States and the favorable timing of tenders to markets outside of the United States. The results were also boosted by the robust uptake of other products, like the Jada system. We expect these products to have continued to witness customer adoption due to their nature, thereby contributing to segmental revenues.However, we expect the segment to have continued to be impacted by lower sales of NuvaRing (estonogestrel /ethinyl estradiol vaginal ring) due to ongoing generic competition.The Zacks Consensus Estimate for the Women’s Health segment’s revenues is currently pegged at $441.3 million, up 0.8% year over year. **Organon & Co. Price and EPS Surprise** [](https://www.zacks.com/stock/chart/OGN/price-eps-surprise?icid=chart-OGN-price-eps-surprise)[Organon & Co. price-eps-surprise](https://www.zacks.com/stock/chart/OGN/price-eps-surprise?icid=chart-OGN-price-eps-surprise) | [Organon & Co. Quote](https://www.nasdaq.com/market-activity/stocks/ogn) **Biosimilars** During the first quarter, the segment was driven by strength in Ontruzant (trastuzumab-dttb), which benefited from incremental demand from a tender in Brazil, Renflexis (infliximab-abda), which grew primarily on the back of continued demand growth in the United States and Canada, and Hadlima (adalimumab-bwwd), primarily resulting from continued uptake following the product's July 2023 launch in the United States. We expect the robust adoption of these products to have continued in the second quarter on the back of sustained demand, thereby significantly pushing up segmental revenues.In April, Organon announced that the Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), had added HADLIMA, an FDA-approved biosimilar to HUMIRA (adalimumab), to its online pharmacy. This is also likely to have aided segmental revenues in the to-be-reported quarter.The Zacks Consensus Estimate for the segment’s revenues is currently pegged at $176.4 million, up 30.7% year over year. **Other Factors to Note** Organon’s Established Brands segment is likely to have been aided by the contribution from the recent commercial agreement for the two migraine drugs, Emgality and Rayvow. In the first quarter, the company saw a recovery in its injectable steroid products. We expect these trends to have continued in the second quarter as well, thereby boosting revenues.However, the current unstable macroeconomic business environment and continued inflationary impacts on material and distribution costs are likely to have weighed on the company’s second-quarter revenues, raising our apprehension. **The Estimate Picture** For second-quarter 2024, the Zacks Consensus Estimate for revenues is pegged at $1.63 billion, implying an improvement of 1.1% from the prior-year quarter’s reported figure.The consensus estimate for EPS is pegged at $1.06, indicating a decrease of 19.1% from the prior-year period’s reported number. **What Our Model Suggests** Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/), has higher chances of beating estimates. This is not the case here, as you can see below. **Earnings ESP:** BD has an Earnings ESP of -1.47%. You can uncover the best stocks to buy or sell before they are reported with our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_article_espfilter&icid=zpi_article_espfilter). **Zacks Rank:**The company currently carries a Zacks Rank #3. **Stocks Worth a Look** Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle. **Esperion Therapeutics, Inc.** [ESPR](https://www.nasdaq.com/market-activity/stocks/espr) has an Earnings ESP of +46.67% and a Zacks Rank of 1. ESPR has an estimated long-term growth rate of 26.2%. You can see ** [the complete list of today’s Zacks #1 Rank stocks here.](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link)**Esperion’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 142.4%. **MediWound Ltd.** [MDWD](https://www.nasdaq.com/market-activity/stocks/mdwd) has an Earnings ESP of +4.76% and is a Zacks Rank #2 stock. MDWD has an estimated growth rate of 23.4% for 2025.MediWound’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 47.7%. **Illumina, Inc.** [ILMN](https://www.nasdaq.com/market-activity/stocks/ilmn) has an Earnings ESP of +132.61% and a Zacks Rank of 1. ILMN has an estimated growth rate of 74.4% for 2024.Illumina’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 788.5%.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_211_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_211&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[Illumina, Inc. (ILMN) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=ILMN&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_211&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=ESPR&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_211&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[MediWound Ltd. (MDWD) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=MDWD&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_211&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[Organon & Co. (OGN) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=OGN&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_211&cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315490/product-demand-likely-to-aid-organon-s-ogn-q2-earnings?cid=CS-NASDAQ-FT-analyst_blog|earnings_preview-2315490)[Zacks Investment Research](https://www.zacks.com/) | Product Demand Likely to Aid Organon's (OGN) Q2 Earnings | News | Zacks | Zacks Equity Research | 0.0552 | 2.33 | 2.19778 | 2.08564 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.03848 | 2.01699 | 2.14787 | 2.07141 | 1.94286 | 1.93029 | 1.88887 |
SAND | Sandstorm Gold Ltd. | Unknown | Unknown | https://www.nasdaq.com/articles/all-you-need-know-about-sandstorm-gold-sand-rating-upgrade-strong-buy | 2024-08-04 02:05:00 | Unknown | Sandstorm Gold (SAND) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Sandstorm Gold basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. **Most Powerful Force Impacting Stock Prices** The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Sandstorm Gold imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. **Harnessing the Power of Earnings Estimate Revisions** As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see [the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). **Earnings Estimate Revisions for Sandstorm Gold** For the fiscal year ending December 2024, this provider of financing for gold mining companies is expected to earn $0.08 per share, which is a change of -42.9% from the year-ago reported number.Analysts have been steadily raising their estimates for Sandstorm Gold. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.8%. **Bottom Line** Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn [more about the Zacks Rank here >>>](https://www.zacks.com/education/stock-education/zacks-rank-guide) The upgrade of Sandstorm Gold to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_523_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315479)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_523&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315479)[Sandstorm Gold Ltd (SAND) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=SAND&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_523&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315479)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315479/all-you-need-to-know-about-sandstorm-gold-sand-rating-upgrade-to-strong-buy?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315479)[Zacks Investment Research](https://www.zacks.com/) | All You Need to Know About Sandstorm Gold (SAND) Rating Upgrade to Strong Buy | News | Zacks | Zacks Equity Research | 0.0552 | 5.74557 | 5.75617 | 5.47742 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.37512 | 5.36676 | 5.23134 | 5.1863 | 5.13647 | 5.46197 | 5.83764 |
SMBC | Southern Missouri Bancorp, Inc. | Finance | Banks | https://www.nasdaq.com/articles/all-you-need-know-about-southern-missouri-bancorp-smbc-rating-upgrade-strong-buy | 2024-08-04 02:12:00 | Stocks | Southern Missouri Bancorp (SMBC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Southern Missouri Bancorp basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. **Most Powerful Force Impacting Stock Prices** The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Southern Missouri Bancorp imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. **Harnessing the Power of Earnings Estimate Revisions** Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see [the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). **Earnings Estimate Revisions for Southern Missouri Bancorp** This bank holding company is expected to earn $4.70 per share for the fiscal year ending June 2025, which represents a year-over-year change of 6.6%.Analysts have been steadily raising their estimates for Southern Missouri Bancorp. Over the past three months, the Zacks Consensus Estimate for the company has increased 10.6%. **Bottom Line** Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.You can learn [more about the Zacks Rank here >>>](https://www.zacks.com/education/stock-education/zacks-rank-guide) The upgrade of Southern Missouri Bancorp to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_523_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315486)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_523&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315486)[Southern Missouri Bancorp, Inc. (SMBC) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=SMBC&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_523&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315486) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315486/all-you-need-to-know-about-southern-missouri-bancorp-smbc-rating-upgrade-to-strong-buy?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2315486)[Zacks Investment Research](https://www.zacks.com/) | All You Need to Know About Southern Missouri Bancorp (SMBC) Rating Upgrade to Strong Buy | News | Zacks | Zacks Equity Research | 0.0552 | 54.5705 | 52.3969 | 52.5076 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.9771 | 49.81 | 49.64 | 50.4834 | 49.0603 | 54.1846 | 56.9761 |
FBIZ | First Business Financial Services, Inc. | Finance | Major Banks | https://www.nasdaq.com/articles/why-first-business-financial-services-fbiz-great-dividend-stock-right-now | 2024-08-04 02:23:00 | Stocks | Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases. **First Business Financial Services in Focus** First Business Financial Services (FBIZ) is headquartered in Madison, and is in the Finance sector. The stock has seen a price change of 9.05% since the start of the year. The bank holding company for First Business Bank and First Business Bank-Milwaukee is currently shelling out a dividend of $0.25 per share, with a dividend yield of 2.29%. This compares to the Banks - Midwest industry's yield of 2.78% and the S&P 500's yield of 1.61%.In terms of dividend growth, the company's current annualized dividend of $1 is up 9.9% from last year. First Business Financial Services has increased its dividend 5 times on a year-over-year basis over the last 5 years for an average annual increase of 11.20%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Right now, First Business Financial Services's payout ratio is 22%, which means it paid out 22% of its trailing 12-month EPS as dividend.FBIZ is expecting earnings to expand this fiscal year as well. The Zacks Consensus Estimate for 2024 is $4.61 per share, with earnings expected to increase 6.47% from the year ago period. **Bottom Line** Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout.For instance, it's a rare occurrence when a tech start-up or big growth business offers their shareholders a dividend. It's more common to see larger companies with more established profits give out dividends. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. That said, they can take comfort from the fact that FBIZ is not only an attractive dividend play, but also represents a compelling investment opportunity with a Zacks Rank of #2 (Buy). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_514_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315446)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_514&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315446)[First Business Financial Services, Inc. (FBIZ) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=FBIZ&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_514&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315446) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315446/why-first-business-financial-services-fbiz-is-a-great-dividend-stock-right-now?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315446)[Zacks Investment Research](https://www.zacks.com/) | Why First Business Financial Services (FBIZ) is a Great Dividend Stock Right Now | News | Zacks | Zacks Equity Research | 0.0552 | 46.054 | 42.2283 | 42.6683 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.7258 | 43.6895 | 41.4543 | 41.6941 | 40.0042 | 42.9571 | 44.8959 |
NRIM | Northrim BanCorp, Inc. | Finance | Savings Institutions | https://www.nasdaq.com/articles/why-northrim-bancorp-nrim-top-dividend-stock-your-portfolio-0 | 2024-08-04 02:23:00 | Stocks | Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns. **Northrim BanCorp in Focus** Northrim BanCorp (NRIM) is headquartered in Anchorage, and is in the Finance sector. The stock has seen a price change of 14.46% since the start of the year. Currently paying a dividend of $0.61 per share, the company has a dividend yield of 3.73%. In comparison, the Banks - West industry's yield is 2.73%, while the S&P 500's yield is 1.61%.Taking a look at the company's dividend growth, its current annualized dividend of $2.44 is up 1.7% from last year. Over the last 5 years, Northrim BanCorp has increased its dividend 5 times on a year-over-year basis for an average annual increase of 17.18%. Any future dividend growth will depend on both earnings growth and the company's payout ratio; a payout ratio is the proportion of a firm's annual earnings per share that it pays out as a dividend. Right now, Northrim's payout ratio is 42%, which means it paid out 42% of its trailing 12-month EPS as dividend.Looking at this fiscal year, NRIM expects solid earnings growth. The Zacks Consensus Estimate for 2024 is $5.57 per share, which represents a year-over-year growth rate of 24.05%. **Bottom Line** Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. However, not all companies offer a quarterly payout.Big, established firms that have more secure profits are often seen as the best dividend options, but it's fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, NRIM is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_514_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315444)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_514&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315444)[Northrim BanCorp Inc (NRIM) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=NRIM&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_514&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315444)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315444/why-northrim-bancorp-nrim-is-a-top-dividend-stock-for-your-portfolio?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_5-2315444)[Zacks Investment Research](https://www.zacks.com/) | Why Northrim BanCorp (NRIM) is a Top Dividend Stock for Your Portfolio | News | Zacks | Zacks Equity Research | 0.0552 | 69.7714 | 62.2499 | 65.2874 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 64.1053 | 63.8517 | 60.8256 | 62.1854 | 61.0572 | 64.8328 | 68.2593 |
COMM | CommScope Holding Company, Inc. | Technology | Radio And Television Broadcasting And Communications Equipment | https://www.nasdaq.com/articles/monolithic-power-mpwr-q2-earnings-beat-higher-revenues | 2024-08-04 02:40:00 | Stocks|MPWR|AKAM|CCOI | **Monolithic Power Systems, Inc.** [MPWR](https://www.nasdaq.com/market-activity/stocks/mpwr) reported strong second-quarter 2024 results, wherein the top and bottom lines beat the respective Zacks Consensus Estimate. Despite declining trends in several verticals, the Kirkland, WA-based company witnessed modest revenue growth year over year, backed by solid momentum in the Enterprise Data vertical. **Net Income** Net income, on a GAAP basis, was $100.4 million or $2.05 per share compared with $99.5 million or $2.04 per share in the prior-year quarter.Non-GAAP net income improved to $155.1 million or $3.17 per share from $137.5 million or $2.82 per share in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 10 cents. **Monolithic Power Systems, Inc. Price and Consensus** [](https://www.zacks.com/stock/chart/MPWR/price-consensus-chart?icid=chart-MPWR-price-consensus-chart)[Monolithic Power Systems, Inc. price-consensus-chart](https://www.zacks.com/stock/chart/MPWR/price-consensus-chart?icid=chart-MPWR-price-consensus-chart) | [Monolithic Power Systems, Inc. Quote](https://www.nasdaq.com/market-activity/stocks/mpwr) **Revenues** Monolithic Power registered revenues of $507.4 million, up from $441.1 million in the prior-year quarter. The top line beat the Zacks Consensus Estimate of $485 million.Revenues from Storage and Computing declined to $114.9 million from $124.5 million in the prior-year quarter. Lower sales of products for storage solutions affected net sales in this vertical. Net sales from Enterprise Data witnessed massive growth to $187.2 million from $48 million in the year-ago quarter, backed by higher sales of server solutions. In the second quarter, the Automotive end market generated $87.2 million in revenues, down from $104.4 million in the prior-year quarter. Lower digital cockpit sales impacted revenues in this segment. In the June quarter, Industrial revenues were $32.3 million compared with $49.7 million in the year-ago quarter. Soft demand for point-of-sale applications impeded this end market’s revenues. The Communications vertical contributed $43.6 million to total revenues compared with $49.3 million in the year-ago quarter. Lower infrastructure sales impeded the top line in this end market. Net sales in the Consumer end market were $42.2 million, down from $65.2 million in the prior-year quarter. Lower gaming revenues impacted the top line. By product family, revenues in DC-to-DC increased to $501.3 million from $418.2 million in the year-ago quarter. In the June quarter, Lighting Control revenues declined to $6.1 million from $22.9 million in the prior-year quarter. **Other Details** During the reported quarter, non-GAAP gross margin was 55.7%, down from 56.5% in the year-ago quarter. Unfavorable variances and higher direct costs impacted the gross margin.Non-GAAP operating expenses were $111.7 million compared with $96 million in the prior-year period. Non-GAAP operating income was $171 million, up from $153.1 million. **Cash Flow & Liquidity** During the quarter, the company generated an operating cash flow of $141 million. As of Jun 30, 2024, cash and cash equivalents aggregated $550.5 million, with $96.7 million in other long-term liabilities. **Outlook** For the third quarter of 2024, management expects revenues in the range of $590-$610 million. Non-GAAP gross margin is projected to be between 55.5% and 56.1%. Non-GAAP operating expenses are estimated to be between $118.3 million and $120.3 million. Total stock-based compensation expenses are expected in the range of $51.7 million-$53.7 million. **Zacks Rank** MPWR currently carries a Zacks Rank #3 (Hold). You can see [the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). **Upcoming Releases****Cogent Communications Holdings, Inc**. [CCOI](https://www.nasdaq.com/market-activity/stocks/ccoi) is scheduled to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at a loss of $1.02 per share, indicating a decline of 684.6% from the year-ago reported figure. **Akamai Technologies, Inc.** [AKAM](https://www.nasdaq.com/market-activity/stocks/akam) is slated to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at $1.54 per share, indicating growth of 3.4% from the year-ago reported figure.Akamai has a long-term earnings growth expectation of 4.8%. AKAM delivered an average earnings surprise of 5.4% in the last four reported quarters. **CommScope Holding Company, Inc.** [COMM](https://www.nasdaq.com/market-activity/stocks/comm) is scheduled to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at $0.06 per share, suggesting a decline of 68.42% from the year-ago reported figure. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_210_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380) [Akamai Technologies, Inc. (AKAM) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=AKAM&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380)[Monolithic Power Systems, Inc. (MPWR) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=MPWR&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380)[CommScope Holding Company, Inc. (COMM) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=COMM&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380)[Cogent Communications Holdings, Inc. (CCOI) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=CCOI&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315380/monolithic-power-mpwr-q2-earnings-beat-on-higher-revenues?cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315380)[Zacks Investment Research](https://www.zacks.com/) | Monolithic Power (MPWR) Q2 Earnings Beat on Higher Revenues | News | Zacks | Zacks Equity Research | 0.0552 | 2.41636 | 2.43724 | 2.22265 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.19082 | 2.03696 | 2.2353 | 2.12161 | 3.99567 | 3.8601 |
COMM | CommScope Holding Company, Inc. | Technology | Radio And Television Broadcasting And Communications Equipment | https://www.nasdaq.com/articles/silicon-motion-simo-tops-q2-earnings-revenue-estimates | 2024-08-04 02:40:00 | Unknown | **Silicon Motion Technology Corporation** [SIMO](https://www.nasdaq.com/market-activity/stocks/simo) reported strong second-quarter 2024 results, wherein both the top and bottom lines surpassed the Zacks Consensus Estimate. The leading merchant supplier of client SSD (Solid State Drive) controllers witnessed top-line growth driven by healthy demand trends. **Net Income** On a GAAP basis, net income improved to $30.8 million or 91 cents per American depositary share (ADS) from $11 million or 33 cents per ADS in the prior-year quarter. Higher net sales across various end markets contributed to the year-over-year improvement in GAAP earnings.Non-GAAP net income was $32.5 million or 96 cents per ADS compared with $12.6 million or 38 cents per ADS in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by a penny. **Silicon Motion Technology Corporation Price and Consensus** [](https://www.zacks.com/stock/chart/SIMO/price-consensus-chart?icid=chart-SIMO-price-consensus-chart)[Silicon Motion Technology Corporation price-consensus-chart](https://www.zacks.com/stock/chart/SIMO/price-consensus-chart?icid=chart-SIMO-price-consensus-chart) | [Silicon Motion Technology Corporation Quote](https://www.nasdaq.com/market-activity/stocks/simo) **Revenues** Quarterly revenues increased to $210.7 million from the year-ago quarter’s tally of $140.4 million. The top line beat the Zacks Consensus Estimate of $207 million. Increased sales of SSD controllers, as well as eMMC and UFS controllers, on a year-over-year basis, contributed to the top-line growth. Net sales increased 11% sequentially in the second quarter.Management noted that sales of SSD controllers increased in the range of 0-5% sequentially and 25-30% on a year-over-year basis. eMMC+UFS (Embedded Multi-Media Card + Universal Flash Storage) sales recorded solid sequential improvement between 25% and 30% and increased 190-195% year over year.Revenues in SSD solutions increased 20-25% sequentially but decreased 5-10% year over year. **Other Details** In the second quarter of 2024, non-GAAP gross profit was $96.8 million compared with $59.7 million in the year-ago quarter, with respective margins of 46% and 42.5%. The rise was primarily driven by higher revenues year over year.Total operating expenses on a non-GAAP basis increased from $48 million to $62.1 million. Non-GAAP operating income improved from $11.7 million to $34.7 million, with margins of 8.3% and 16.5%, respectively. **Cash Flow & Liquidity** For the first six months of 2024, Silicon Motion generated $29.3 million of cash from operating activities compared with a cash flow of $43 million in the year-ago period. As of Jun 30, 2024, the company had $289.2 million in cash and cash equivalents with $60.2 million of other liabilities. In the second quarter of 2024, the company’s capital expenditure totaled $10.4 million, including $6.3 million for the routine procurement of testing tools, software, design tools and other goods. **Outlook** For third-quarter 2024, the company estimates non-GAAP revenues in the range of $205-216 million. Non-GAAP gross margin is expected to be around 46-47%. Non-GAAP operating margin is anticipated to be in the band of 14.3-15.3%.For full-year 2024, management projects non-GAAP revenues in the range of $800-$830 million. Non-GAAP gross margin is expected to be around 46-47%. Non-GAAP operating margin is anticipated to be in the band of 14.8-16.8%. Per management, the company’s new cost-effective, high-quality, and unique solutions are anticipated to scale further throughout the year. **Zacks Rank** Silicon Motion currently carries a Zacks Rank #3 (Hold).You can see [the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). **Upcoming Releases****Cogent Communications Holdings, Inc.** [CCOI](https://www.nasdaq.com/market-activity/stocks/ccoi) is scheduled to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at a loss of $1.02 per share, indicating a decline of 684.6% from the year-ago reported figure. **Akamai Technologies, Inc.** [AKAM](https://www.nasdaq.com/market-activity/stocks/akam) is slated to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at $1.54 per share, indicating growth of 3.4% from the year-ago reported figure.Akamai has a long-term earnings growth expectation of 4.8%. AKAM delivered an average earnings surprise of 5.4% in the last four reported quarters. **CommScope Holding Company, Inc.** [COMM](https://www.nasdaq.com/market-activity/stocks/comm) is scheduled to release second-quarter 2024 earnings on Aug 8. The Zacks Consensus Estimate for earnings is pegged at $0.06 per share, suggesting a decline of 68.42% from the year-ago reported figure. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_210_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[Akamai Technologies, Inc. (AKAM) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=AKAM&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[Silicon Motion Technology Corporation (SIMO) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=SIMO&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[CommScope Holding Company, Inc. (COMM) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=COMM&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[Cogent Communications Holdings, Inc. (CCOI) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=CCOI&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315379/silicon-motion-simo-tops-q2-earnings-revenue-estimates?cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315379)[Zacks Investment Research](https://www.zacks.com/) | Silicon Motion (SIMO) Tops Q2 Earnings & Revenue Estimates | News | Zacks | Zacks Equity Research | 0.0552 | 2.41636 | 2.43724 | 2.22265 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.17956 | 2.19082 | 2.03696 | 2.2353 | 2.12161 | 3.99567 | 3.8601 |
GWRS | Global Water Resources, Inc. | Utilities | Water Supply | https://www.nasdaq.com/articles/york-water-yorw-misses-q2-earnings-and-revenue-estimates | 2024-08-04 02:47:00 | Stocks|YORW | York Water (YORW) came out with quarterly earnings of $0.35 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this purifying and distribution company would post earnings of $0.29 per share when it actually produced earnings of $0.30, delivering a surprise of 3.45%. Over the last four quarters, the company has surpassed consensus EPS estimates three times.York Water, which belongs to the Zacks Utility - Water Supply industry, posted revenues of $18.75 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 1.32%. This compares to year-ago revenues of $18.77 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.York Water shares have added about 6.6% since the beginning of the year versus the S&P 500's gain of 14.2%. **What's Next for York Water?**While York Water has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this [earnings release](https://www.zacks.com/stock/research/YORW/earnings-calendar), the estimate revisions trend for York Water: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see [the complete list of today's Zacks #1 Rank (Strong Buy) stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi_1link).It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.48 on $19 million in revenues for the coming quarter and $1.61 on $74 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Utility - Water Supply is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Global Water Resources, Inc. (GWRS), another stock in the same industry, has yet to report results for the quarter ended June 2024. The results are expected to be released on August 8.This company is expected to post quarterly earnings of $0.08 per share in its upcoming report, which represents a year-over-year change of +14.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.Global Water Resources, Inc.'s revenues are expected to be $13.6 million, up 4.6% from the year-ago quarter. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_513_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_4-2315368)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_513&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_4-2315368)[The York Water Company (YORW) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=YORW&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_513&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_4-2315368)[Global Water Resources, Inc. (GWRS) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=GWRS&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_513&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_4-2315368) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315368/york-water-yorw-misses-q2-earnings-and-revenue-estimates?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_4-2315368)[Zacks Investment Research](https://www.zacks.com/) | York Water (YORW) Misses Q2 Earnings and Revenue Estimates | News | Zacks | Zacks Equity Research | 0.0552 | 13.1967 | 12.6993 | 12.9824 | 12.66 | 12.66 | 12.66 | 12.66 | 12.66 | 12.66 | 12.66 | 12.66 | 12.66 | 12.6145 | 12.1725 | 12.2242 | 12.1004 | 11.979 | 12.5808 |
XERS | Xeris Biopharma Holdings, Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/earnings-preview-amneal-pharmaceuticals-amrx-q2-earnings-expected-decline | 2024-08-04 02:59:00 | Stocks|AMRX | The market expects Amneal Pharmaceuticals (AMRX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 9, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the [earnings call](https://www.nasdaq.com/market-activity/earnings) will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. **Zacks Consensus Estimate** This pharmaceutical company is expected to post quarterly earnings of $0.14 per share in its upcoming report, which represents a year-over-year change of -26.3%.Revenues are expected to be $657.43 million, up 9.8% from the year-ago quarter. **Estimate Revisions Trend** The consensus EPS estimate for the quarter has been revised 4.35% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. **Earnings Whisper** Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction) -- has this insight at its core.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises), and a solid Zacks Rank actually increases the predictive power of Earnings ESP.Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). **How Have the Numbers Shaped Up for Amneal?**For Amneal, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -16.28%.On the other hand, the stock currently carries a Zacks Rank of #1.So, this combination makes it difficult to conclusively predict that Amneal will beat the consensus EPS estimate. **Does Earnings Surprise History Hold Any Clue?**While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.For the last reported quarter, it was expected that Amneal would post earnings of $0.09 per share when it actually produced earnings of $0.14, delivering a surprise of +55.56%. Over the last four quarters, the company has beaten consensus EPS estimates four times. **Bottom Line** An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported.Amneal doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. **An Industry Player's Expected Results** Another stock from the Zacks Medical - Drugs industry, Xeris Biopharma (XERS), is soon expected to post loss of $0.11 per share for the quarter ended June 2024. This estimate indicates a year-over-year change of +21.4%. Revenues for the quarter are expected to be $47.05 million, up 23.8% from the year-ago quarter. The consensus EPS estimate for Xeris Biopharma has been revised 6.4% higher over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -3.77%.When combined with a Zacks Rank of #2 (Buy), this Earnings ESP makes it difficult to conclusively predict that Xeris Biopharma will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_518_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315310)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315310)[AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=AMRX&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315310)[Xeris Biopharma Holdings, Inc. (XERS) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=XERS&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315310) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315310/earnings-preview-amneal-pharmaceuticals-amrx-q2-earnings-expected-to-decline?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315310)[Zacks Investment Research](https://www.zacks.com/) | Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline | News | Zacks | Zacks Equity Research | 0.0552 | 2.49395 | 2.39157 | 2.38227 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.22338 | 2.19686 | 2.28305 | 2.2833 | 2.19295 | 2.71245 | 2.78428 |
HIVE | HIVE Blockchain Technologies Ltd. | Finance | Finance: Consumer Services | https://www.nasdaq.com/articles/will-hive-digital-technologies-hive-report-negative-q1-earnings-what-you-should-know | 2024-08-04 02:59:00 | Stocks|OPRT | Wall Street expects a year-over-year increase in earnings on higher revenues when HIVE Digital Technologies (HIVE) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The [earnings report](https://www.zacks.com/stock/research/HIVE/earnings-calendar) might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the [earnings call](https://www.nasdaq.com/market-activity/earnings) it's worth handicapping the probability of a positive EPS surprise. **Zacks Consensus Estimate** This crypto currency mining company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of +55.6%.Revenues are expected to be $31.85 million, up 35.1% from the year-ago quarter. **Estimate Revisions Trend** The consensus EPS estimate for the quarter has been revised 17.65% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. **Earnings Whisper** Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction).The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises), and a solid Zacks Rank actually increases the predictive power of Earnings ESP.Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). **How Have the Numbers Shaped Up for HIVE Digital Technologies?**For HIVE Digital Technologies, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.On the other hand, the stock currently carries a Zacks Rank of #2.So, this combination makes it difficult to conclusively predict that HIVE Digital Technologies will beat the consensus EPS estimate. **Does Earnings Surprise History Hold Any Clue?**While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.For the last reported quarter, it was expected that HIVE Digital Technologies would post a loss of $0.13 per share when it actually produced a loss of $0.03, delivering a surprise of +76.92%. Over the last four quarters, the company has beaten consensus EPS estimates two times. **Bottom Line** An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported.HIVE Digital Technologies doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. **An Industry Player's Expected Results** Among the stocks in the Zacks Financial - Miscellaneous Services industry, Oportun Financial Corporation (OPRT) is soon expected to post loss of $0.18 per share for the quarter ended June 2024. This estimate indicates a year-over-year change of -400%. This quarter's revenue is expected to be $246.12 million, down 7.7% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Oportun Financial has been revised 66.7% up to the current level. Nevertheless, the company now has an Earnings ESP of 0.00%, reflecting an equal Most Accurate Estimate.When combined with a Zacks Rank of #1 (Strong Buy), this Earnings ESP makes it difficult to conclusively predict that Oportun Financial will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_518_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315307)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315307)[HIVE Digital Technologies Ltd. (HIVE) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=HIVE&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315307)[Oportun Financial Corporation (OPRT) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=OPRT&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315307)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315307/will-hive-digital-technologies-hive-report-negative-q1-earnings-what-you-should-know?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315307)[Zacks Investment Research](https://www.zacks.com/) | Will HIVE Digital Technologies (HIVE) Report Negative Q1 Earnings? What You Should Know | News | Zacks | Zacks Equity Research | 0.0552 | 3.66332 | 3.38085 | 3.29637 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.90147 | 2.87409 | 2.90991 | 2.90328 | 2.7688 | 3.04755 | 3.10899 |
ECO | Okeanis Eco Tankers Corp. | Consumer Discretionary | Marine Transportation | https://www.nasdaq.com/articles/analysts-estimate-okeanis-eco-tankers-corp-eco-report-decline-earnings-what-look-out | 2024-08-04 02:59:00 | Unknown | The market expects Okeanis Eco Tankers Corp. (ECO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The [earnings report](https://www.zacks.com/stock/research/ECO/earnings-calendar) might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the [earnings call](https://www.nasdaq.com/market-activity/earnings) it's worth handicapping the probability of a positive EPS surprise. **Zacks Consensus Estimate** This company is expected to post quarterly earnings of $0.90 per share in its upcoming report, which represents a year-over-year change of -45.5%.Revenues are expected to be $100.71 million, down 15.9% from the year-ago quarter. **Estimate Revisions Trend** The consensus EPS estimate for the quarter has been revised 2.38% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. **Earnings Whisper** Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction) -- has this insight at its core.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises), and a solid Zacks Rank actually increases the predictive power of Earnings ESP.Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). **How Have the Numbers Shaped Up for Okeanis Eco Tankers Corp. **For Okeanis Eco Tankers Corp.The Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.On the other hand, the stock currently carries a Zacks Rank of #2.So, this combination makes it difficult to conclusively predict that Okeanis Eco Tankers Corp. Will beat the consensus EPS estimate. **Does Earnings Surprise History Hold Any Clue?**While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.For the last reported quarter, it was expected that Okeanis Eco Tankers Corp. Would post earnings of $1.10 per share when it actually produced earnings of $1.23, delivering a surprise of +11.82%. Over the last four quarters, the company has beaten consensus EPS estimates just once. **Bottom Line** An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported.Okeanis Eco Tankers Corp. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. **An Industry Player's Expected Results** Among the stocks in the Zacks Transportation - Shipping industry, Euroseas Ltd. (ESEA) is soon expected to post earnings of $2.49 per share for the quarter ended June 2024. This estimate indicates a year-over-year change of -40.3%. This quarter's revenue is expected to be $49.33 million, up 0% from the year-ago quarter. The consensus EPS estimate for Euroseas has been revised 7.3% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0.00%.When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Euroseas will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_518_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315315)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315315)[Okeanis Eco Tankers Corp. (ECO) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=ECO&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315315)[Euroseas Ltd. (ESEA) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=ESEA&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315315)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315315/analysts-estimate-okeanis-eco-tankers-corp-eco-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315315)[Zacks Investment Research](https://www.zacks.com/) | Analysts Estimate Okeanis Eco Tankers Corp. (ECO) to Report a Decline in Earnings: What to Look Out for | News | Zacks | Zacks Equity Research | 0.0552 | 31.8815 | 30.6375 | 29.8617 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2648 | 28.2016 | 29.0328 | 29.7848 | 29.1242 | 31.3571 | 30.8357 |
CGC | Canopy Growth Corporation | Health Care | Medicinal Chemicals and Botanical Products | https://www.nasdaq.com/articles/canopy-growth-corporation-cgc-may-report-negative-earnings-know-trend-ahead-next-weeks | 2024-08-04 03:07:00 | Stocks|NVST | The market expects Canopy Growth Corporation (CGC) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 9, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the [earnings call](https://www.nasdaq.com/market-activity/earnings) it's worth handicapping the probability of a positive EPS surprise. **Zacks Consensus Estimate** This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of +22.5%.Revenues are expected to be $51.82 million, down 36% from the year-ago quarter. **Estimate Revisions Trend** The consensus EPS estimate for the quarter has been revised 1.47% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. **Earnings Whisper** Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction).The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises), and a solid Zacks Rank actually increases the predictive power of Earnings ESP.Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). **How Have the Numbers Shaped Up for Canopy Growth?**For Canopy Growth, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -8.51%.On the other hand, the stock currently carries a Zacks Rank of #2.So, this combination makes it difficult to conclusively predict that Canopy Growth will beat the consensus EPS estimate. **Does Earnings Surprise History Hold Any Clue?**While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.For the last reported quarter, it was expected that Canopy Growth would post a loss of $0.33 per share when it actually produced a loss of $0.28, delivering a surprise of +15.15%. Over the last four quarters, the company has beaten consensus EPS estimates two times. **Bottom Line** An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported.Canopy Growth doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. **Expected Results of an Industry Player** Among the stocks in the Zacks Medical - Products industry, Envista (NVST) is soon expected to post earnings of $0.27 per share for the quarter ended June 2024. This estimate indicates a year-over-year change of -37.2%. This quarter's revenue is expected to be $647.99 million, down 2.2% from the year-ago quarter. The consensus EPS estimate for Envista has been revised 4.2% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -3.20%.When combined with a Zacks Rank of #5 (Strong Sell), this Earnings ESP makes it difficult to conclusively predict that Envista will beat the consensus EPS estimate. Over the last four quarters, the company surpassed EPS estimates just once.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_518_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315314)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315314)[Canopy Growth Corporation (CGC) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=CGC&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315314)[Envista Holdings Corporation (NVST) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=NVST&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315314)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315314/canopy-growth-corporation-cgc-may-report-negative-earnings-know-the-trend-ahead-of-next-week-s-release?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315314)[Zacks Investment Research](https://www.zacks.com/) | Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release | News | Zacks | Zacks Equity Research | 0.0552 | 7.62264 | 6.70264 | 6.53038 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.2945 | 6.13368 | 6.39767 | 6.44456 | 6.26914 | 6.97105 | 5.25631 |
BRY | Berry Corporation | Energy | Oil & Gas Production | https://www.nasdaq.com/articles/berry-petroleum-bry-reports-next-week-wall-street-expects-earnings-growth | 2024-08-04 03:07:00 | Stocks|OXY | Berry Petroleum (BRY) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 9. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the [earnings call](https://www.nasdaq.com/market-activity/earnings) it's worth handicapping the probability of a positive EPS surprise. **Zacks Consensus Estimate** This independent upstream energy company is expected to post quarterly earnings of $0.20 per share in its upcoming report, which represents a year-over-year change of +33.3%.Revenues are expected to be $169.35 million, down 26.2% from the year-ago quarter. **Estimate Revisions Trend** The consensus EPS estimate for the quarter has been revised 1.69% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. **Earnings Whisper** Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks [Earnings ESP](https://www.zacks.com/earnings/earnings-surprise-predictions/) (Expected Surprise Prediction) -- has this insight at its core.The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce [a positive surprise nearly 70% of the time](https://www.zacks.com/stock/news/302256/zacks-earnings-esp-a-better-way-to-find-earnings-surprises), and a solid Zacks Rank actually increases the predictive power of Earnings ESP.Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). **How Have the Numbers Shaped Up for Berry Petroleum?**For Berry Petroleum, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +37.71%.On the other hand, the stock currently carries a Zacks Rank of #3.So, this combination indicates that Berry Petroleum will most likely beat the consensus EPS estimate. **Does Earnings Surprise History Hold Any Clue?**Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.For the last reported quarter, it was expected that Berry Petroleum would post earnings of $0.18 per share when it actually produced earnings of $0.14, delivering a surprise of -22.22%. Over the last four quarters, the company has beaten consensus EPS estimates just once. **Bottom Line** An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our [Earnings ESP Filter](https://www.zacks.com/premium/esp-buy?adid=zp_topnav_espfilter&icid=zpi_topnav_espfilter) to uncover the best stocks to buy or sell before they've reported.Berry Petroleum appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. **Expected Results of an Industry Player** Among the stocks in the Zacks Oil and Gas - Integrated - United States industry, Occidental Petroleum (OXY) is soon expected to post earnings of $0.80 per share for the quarter ended June 2024. This estimate indicates a year-over-year change of +17.7%. This quarter's revenue is expected to be $7.18 billion, up 6.6% from the year-ago quarter. The consensus EPS estimate for Occidental has been revised 5.2% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -9.97%.When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that Occidental will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates two times.Stay on top of upcoming earnings announcements with the [Zacks Earnings Calendar](https://www.zacks.com/earnings/earnings-calendar). **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_518_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315313)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315313)[Berry Corporation (BRY) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=BRY&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315313)[Occidental Petroleum Corporation (OXY) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=OXY&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_518&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315313)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315313/berry-petroleum-bry-reports-next-week-wall-street-expects-earnings-growth?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_9-2315313)[Zacks Investment Research](https://www.zacks.com/) | Berry Petroleum (BRY) Reports Next Week: Wall Street Expects Earnings Growth | News | Zacks | Zacks Equity Research | 0.0552 | 6.74682 | 6.51944 | 6.17869 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.99763 | 5.98613 | 5.87254 | 5.89522 | 5.92966 | 6.50447 | 6.23126 |
HBCP | Home Bancorp, Inc. | Finance | Banks | https://www.nasdaq.com/articles/should-value-investors-buy-home-bancorp-hbcp-stock-0 | 2024-08-04 03:33:00 | Stocks | While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits. In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.One company value investors might notice is **Home Bancorp (HBCP)**. HBCP is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock is trading with a P/E ratio of 10.14, which compares to its industry's average of 11.66. Over the past 52 weeks, HBCP's Forward P/E has been as high as 10.78 and as low as 7.77, with a median of 8.83.Another notable valuation metric for HBCP is its P/B ratio of 0.96. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 2.06. Within the past 52 weeks, HBCP's P/B has been as high as 1.02 and as low as 0.74, with a median of 0.81.Value investors also use the P/S ratio. The P/S ratio is is calculated as price divided by sales. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. HBCP has a P/S ratio of 1.78. This compares to its industry's average P/S of 1.98.Finally, our model also underscores that HBCP has a P/CF ratio of 8.03. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 18.05. Over the past year, HBCP's P/CF has been as high as 8.26 and as low as 5.05, with a median of 6.21. Value investors will likely look at more than just these metrics, but the above data helps show that Home Bancorp is likely undervalued currently. And when considering the strength of its earnings outlook, HBCP sticks out at as one of the market's strongest value stocks. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_510_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_2-2315207)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_510&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_2-2315207)[Home Bancorp, Inc. (HBCP) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=HBCP&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_510&cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_2-2315207)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315207/should-value-investors-buy-home-bancorp-hbcp-stock?cid=CS-NASDAQ-FT-tale_of_the_tape|yseop_template_2-2315207)[Zacks Investment Research](https://www.zacks.com/) | Should Value Investors Buy Home Bancorp (HBCP) Stock? | News | Zacks | Zacks Equity Research | 0.0552 | 43.9228 | 40.0629 | 40.2201 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 39.0678 | 38.9592 | 38.7078 | 39.1876 | 39.4193 | 41.8397 | 44.0871 |
PEPG | PepGen Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/down-3963-4-weeks-heres-why-you-should-you-buy-dip-pepgen-pepg | 2024-08-04 03:51:00 | Stocks | **PepGen, Inc.** (PEPG) has been beaten down lately with too much selling pressure. While the stock has lost 39.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. **Guide to Identifying Oversold Stocks** We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision. **Here's Why PEPG Could Experience a Turnaround** The RSI reading of 23.57 for PEPG is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand. [3-month RSI Chart for PEPG](https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/PEPG_RCI14.jpeg) This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering PEPG in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 2.2% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.Moreover, PEPG currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see [the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>](https://www.zacks.com/registration/premium/login/?continue_to=/stocks/buy-list&adid=ZCOM_ZP_ARTCAT_TALEOFTAPE_544_080224&icid=blog-tale_of_the_tape|rsi-ARTCAT|080224-ZP-commentary_blog-text-eoac)**Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_544_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|rsi-2315183)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_544&cid=CS-NASDAQ-FT-tale_of_the_tape|rsi-2315183)[PepGen, Inc. (PEPG) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=PEPG&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_544&cid=CS-NASDAQ-FT-tale_of_the_tape|rsi-2315183)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315183/down-39-63-in-4-weeks-here-s-why-you-should-you-buy-the-dip-in-pepgen-pepg?cid=CS-NASDAQ-FT-tale_of_the_tape|rsi-2315183)[Zacks Investment Research](https://www.zacks.com/) | Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG) | News | Zacks | Zacks Equity Research | 0.0552 | 14.078 | 10.0352 | 9.81239 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.42206 | 9.39387 | 9.11705 | 9.41823 | 8.91591 | 9.32192 | 9.54887 |
CLDT | Chatham Lodging Trust | Real Estate | Real Estate Investment Trusts | https://www.nasdaq.com/articles/chatham-lodging-cldt-q2-earnings-how-key-metrics-compare-wall-street-estimates | 2024-08-04 03:57:00 | Technology | Chatham Lodging (CLDT) reported $86.48 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 2.4%. EPS of $0.39 for the same period compares to $0.15 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $85.48 million, representing a surprise of +1.17%. The company delivered an EPS surprise of +8.33%, with the consensus EPS estimate being $0.36. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Chatham Lodging performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: - **Revenue- Room**: $79.04 million versus the three-analyst average estimate of $78.72 million. The reported number represents a year-over-year change of +2%. - **Revenue- Reimbursable costs from related parties**: $0.28 million compared to the $0.33 million average estimate based on two analysts. The reported number represents a change of -24.7% year over year. - **Net Income (loss) attributable to per common shareholders (Diluted)**: $0.10 versus $0.07 estimated by three analysts on average. [View all Key Company Metrics for Chatham Lodging here>>>](https://www.zacks.com/stock/research/CLDT/key-company-metrics-details?adid=ZCOM_ZP_ARTCAT_FUNDAMENTALANALYSIS_574_080224) Shares of Chatham Lodging have returned +3.2% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_FUNDAMENTALANALYSIS_574_08022024&cid=CS-NASDAQ-FT-fundamental_analysis|nfm-2315157)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_FUNDAMENTALANALYSIS_574&cid=CS-NASDAQ-FT-fundamental_analysis|nfm-2315157)[Chatham Lodging Trust (REIT) (CLDT) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=CLDT&ADID=SYND_NASDAQ_TCK_FUNDAMENTALANALYSIS_574&cid=CS-NASDAQ-FT-fundamental_analysis|nfm-2315157) [To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315157/chatham-lodging-cldt-q2-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-NASDAQ-FT-fundamental_analysis|nfm-2315157)[Zacks Investment Research](https://www.zacks.com/) | Chatham Lodging (CLDT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates | News | Zacks | Zacks Equity Research | 0.0552 | 12.0095 | 11.1174 | 20.5068 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.92416 | 8.34047 | 7.87837 | 7.84579 | 11.9431 | 15.7846 | 8.54256 |
MAX | MediaAlpha, Inc. | Consumer Discretionary | Business Services | https://www.nasdaq.com/articles/mediaalpha-inc-max-crossed-above-200-day-moving-average-what-means-investors | 2024-08-04 04:06:00 | Stocks | MediaAlpha, Inc. (MAX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MAX broke through the 200-day moving average, which suggests a long-term bullish trend.The 200-day simple moving average helps traders and analysts determine overall long-term market trends for stocks, commodities, indexes, and other financial instruments. The indicator moves higher or lower along with longer-term price moves, serving as a support or resistance level. MAX has rallied 32.5% over the past four weeks, and the company is a Zacks Rank #1 (Strong Buy) at the moment. This combination suggests MAX could be on the verge of another move higher.Looking at MAX's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.Investors may want to watch MAX for more gains in the near future given the company's key technical level and positive earnings estimate revisions. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_538_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|200_day_moving_average_yseop-2315177)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_538&cid=CS-NASDAQ-FT-tale_of_the_tape|200_day_moving_average_(yseop)-2315177)[MediaAlpha, Inc. (MAX) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=MAX&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_538&cid=CS-NASDAQ-FT-tale_of_the_tape|200_day_moving_average_(yseop)-2315177)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315177/mediaalpha-inc-max-crossed-above-the-200-day-moving-average-what-that-means-for-investors?cid=CS-NASDAQ-FT-tale_of_the_tape|200_day_moving_average_(yseop)-2315177)[Zacks Investment Research](https://www.zacks.com/) | MediaAlpha, Inc. (MAX) Crossed Above the 200-Day Moving Average: What That Means for Investors | News | Zacks | Zacks Equity Research | 0.0552 | 14.5081 | 16.3317 | 16.4053 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.7946 | 16.4638 | 16.5167 | 16.227 | 17.271 | 18.2494 |
ML | MoneyLion Inc. | Finance | Finance: Consumer Services | https://www.nasdaq.com/articles/moneylion-ml-buy-wall-street-analysts-look-optimistic | 2024-08-04 04:06:00 | Technology | Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about **MoneyLion Inc.** (ML) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. MoneyLion currently has an average brokerage recommendation (ABR) of 1.25, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by four brokerage firms. An ABR of 1.25 approximates between Strong Buy and Buy.Of the four recommendations that derive the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 25% of all recommendations. **Brokerage Recommendation Trends for ML** [Broker Rating Breakdown Chart for ML](https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/ML_08022024.png) [Check price target & stock forecast for MoneyLion here>>>](https://www.zacks.com/stock/research/ML/price-target-stock-forecast?adid=ZCOM_ZP_ARTCAT_FUNDAMENTALANALYSIS_573_080224) The ABR suggests buying MoneyLion, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. **ABR Should Not Be Confused With Zacks Rank** In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. **Is ML Worth Investing In?**Looking at the earnings estimate revisions for MoneyLion, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $1.45.Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for MoneyLion. You can see [the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>](https://www.zacks.com/stocks/buy-list/?adid=ZCOM_ZP_ARTCAT_FUNDAMENTALANALYSIS_573_080224&icid=blog-fundamental_analysis|average_broker_rating-ARTCAT|080224-ZP-commentary_blog-text-eoac) It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for MoneyLion. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_FUNDAMENTALANALYSIS_573_08022024&cid=CS-NASDAQ-FT-fundamental_analysis|average_broker_rating-2315170)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_FUNDAMENTALANALYSIS_573&cid=CS-NASDAQ-FT-fundamental_analysis|average_broker_rating-2315170)[MoneyLion Inc. (ML) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=ML&ADID=SYND_NASDAQ_TCK_FUNDAMENTALANALYSIS_573&cid=CS-NASDAQ-FT-fundamental_analysis|average_broker_rating-2315170)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315170/is-moneylion-ml-a-buy-as-wall-street-analysts-look-optimistic?cid=CS-NASDAQ-FT-fundamental_analysis|average_broker_rating-2315170)[Zacks Investment Research](https://www.zacks.com/) | Is MoneyLion (ML) a Buy as Wall Street Analysts Look Optimistic? | News | Zacks | Zacks Equity Research | 0.0552 | 67.7436 | 64.3449 | 2.86277 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 40.5888 | 61.0201 | 48.8502 | 44.3174 | 43.8757 | 46.1454 |
BB | BlackBerry Limited | Technology | Computer Software: Prepackaged Software | https://www.nasdaq.com/articles/bces-q2-earnings-revenues-miss-estimates-decrease-y-y | 2024-08-04 04:13:00 | Stocks|SAP|BMI|BCE | **BCE Inc.** [BCE](https://www.nasdaq.com/market-activity/stocks/bce) reported second-quarter 2024 adjusted earnings per share (EPS) of C$0.78 (57 cents), down 1.3% year over year. The Zacks Consensus Estimate was pegged at 59 cents.Quarterly total operating revenues fell 1% year over year to C$6,005 million ($4,388.9 million). The consensus estimate was pegged at $4,459.7 million. The contraction resulted from an 8.7% decrease in Product revenues, which totaled C$697 million, amid 0.1% growth in Service revenues, which came in at C$5,308 million. **BCE, Inc. Price, Consensus and EPS Surprise [](https://www.zacks.com/stock/chart/BCE/price-consensus-eps-surprise-chart?icid=chart-BCE-price-consensus-eps-surprise-chart)** [BCE, Inc. price-consensus-eps-surprise-chart](https://www.zacks.com/stock/chart/BCE/price-consensus-eps-surprise-chart?icid=chart-BCE-price-consensus-eps-surprise-chart) | [BCE, Inc. Quote](https://www.nasdaq.com/market-activity/stocks/bce) **Segmental Results** The company has combined its Bell Wireless and Bell Wireline operating segments to form a segment called Bell CTS. BCE now reports its segment results under Bell CTS and Bell Media. **Bell CTS**’ operating revenues dipped 1.3% year over year to C$5,283 million due to soft demand trends in product revenue.Within Bell CTS segment, Service revenue fell 0.1% to C$4,586 million, hurt by ongoing declines in legacy services but bolstered by growth in mobile phone and business solutions services. Product revenues were down $66 million, which represented 93% of the 1.3% fall in total revenues. The downside was mainly due to reduced sales of mobile phones with 70% of new activations on BYOD. This was further hampered by revenue loss from The Source and declining business wireline data product sales, post supply chain recovery in 2023.Postpaid mobile phone net subscriber activations were 78,500, down 29.5% year over year. The number of postpaid mobile phone net subscriber activations decreased owing to rising mobile phone postpaid customer churn driven by growing competitive market activity and promotional offers on postpaid plans. This was partly balanced by higher gross subscriber activations, continued 5G and multi-product bundling momentum and effective promotions.Prepaid mobile phone net subscriber activations were 52,543, up 268.5% year over year. The primary driver behind the expansion was a 19.9% rise in gross activations due to augmented retail distribution and effective Lucky Mobile marketing strategies coupled with a lower customer churn rate, which jumped 8 basis points to 4.60%. **Bell Media** generated revenues of C$812 million, increasing 0.9% year over year. The uptick was the result of a 1.9% rise in advertising revenues driven by solid TV sports specialty performance along with continued strength in digital advertising. The F1 Canadian Grand Prix and increasing international sales of Bell Media programming contributed to this revenue performance. The acquisition of OUTFRONT Media in June 2024 was another tailwind. **Other Details** Adjusted EBITDA in the reported quarter grew 2% to C$2,697 million, driven by a 2% increase at Bell CTS and a 1.9% rise at Bell Media. The adjusted EBITDA margin improved to 44.9%, up from 43.6% in the prior-year quarter, reflecting operational efficiencies and cost management. **Cash Flow** BCE generated C$2,137 million of cash from operating activities compared with C$2,365 million in the prior-year quarter. The free cash flow was C$1,097 million compared with C$1016 million a year ago due to higher cash flows from operating activities. **2024 Guidance** BCE reiterated its financial outlook for 2024. It expects revenues to stay flat to grow 4% and adjusted EBITDA growth between 1.5% and 4.5%.Free cash flow growth is projected to be in the band of (3)-(11)%. The annualized common dividend per share is estimated to be C$3.99. **Zacks Rank** BCE currently has a Zacks Rank #3 (Hold). You can see [the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here](https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&ICID=zpi%20_1link). **Performance of Other Companies****BlackBerry**’s [BB](https://www.nasdaq.com/market-activity/stocks/bb) first-quarter fiscal 2025 adjusted loss per share of 3 cents was narrower than the company’s estimate of a loss of 4-6 cents. In the year-ago quarter, it reported non-GAAP earnings of 6 cents per share. The Zacks Consensus Estimate was pegged at a loss of 4 cents per share. Shares of BB have lost 51.8% in the past year. **Badger Meter, Inc** [BMI](https://www.nasdaq.com/market-activity/stocks/bmi) reported earnings per share (EPS) of $1.12 for second-quarter 2024, beating the Zacks Consensus Estimate by 14.3%. Also, the bottom line compared favorably with the year-ago quarter’s EPS of 76 cents.Shares of BMI have gained 23.5% in the past year. **SAP SE** [SAP](https://www.nasdaq.com/market-activity/stocks/sap) reported second-quarter 2024 non-IFRS earnings of €1.10 ($1.18) per share, climbing 59% from the year-ago quarter’s levels. The Zacks Consensus Estimate was pegged at $1.01.In the past year, shares of SAP have gained 55.5%. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_ANALYSTBLOG_210_08022024&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[Badger Meter, Inc. (BMI) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BMI&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[SAP SE (SAP) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=SAP&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[BCE, Inc. (BCE) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BCE&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[BlackBerry Limited (BB) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=ZER_CONF&t=BB&ADID=SYND_NASDAQ_TCK_ANALYSTBLOG_210&cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315360/bce-s-q2-earnings-revenues-miss-estimates-decrease-y-y?cid=CS-NASDAQ-FT-analyst_blog|earnings_article-2315360)[Zacks Investment Research](https://www.zacks.com/) | BCE's Q2 Earnings & Revenues Miss Estimates, Decrease Y/Y | News | Zacks | Zacks Equity Research | 0.0552 | 2.3967 | 2.28203 | 2.2092 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.20536 | 2.12915 | 2.18251 | 2.13057 | 2.10893 | 2.34782 | 2.34035 |
MAX | MediaAlpha, Inc. | Consumer Discretionary | Business Services | https://www.nasdaq.com/articles/mediaalpha-inc-max-recently-broke-out-above-50-day-moving-average | 2024-08-04 04:13:00 | Stocks | From a technical perspective, MediaAlpha, Inc. (MAX) is looking like an interesting pick, as it just reached a key level of support. MAX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend. Shares of MAX have been moving higher over the past four weeks, up 32.5%. Plus, the company is currently a Zacks Rank #1 (Strong Buy) stock, suggesting that MAX could be poised for a continued surge.Looking at MAX's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.With a winning combination of earnings estimate revisions and hitting a key technical level, investors should keep their eye on MAX for more gains in the near future. **Research Chief Names "Single Best Pick to Double"** From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. [Free: See Our Top Stock And 4 Runners Up](https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&adid=SYND_NASDAQ_ZU_1S2DREPORTGLOBAL_TALEOFTAPE_537_08022024&cid=CS-NASDAQ-FT-tale_of_the_tape|50_day_moving_average_yseop-2315180)[Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report](https://www.zacks.com/registration/pfp/?ALERT=RPT_7BEST_NASDAQSYND&ADID=SYND_NASDAQ_7BEST_TALEOFTAPE_537&cid=CS-NASDAQ-FT-tale_of_the_tape|50_day_moving_average_(yseop)-2315180)[MediaAlpha, Inc. (MAX) : Free Stock Analysis Report](https://www.zacks.com/registration/pfp?ALERT=NASDAQ_ZER_A388&d_alert=rd_final_rank&t=MAX&ADID=SYND_NASDAQ_TCK_TALEOFTAPE_537&cid=CS-NASDAQ-FT-tale_of_the_tape|50_day_moving_average_(yseop)-2315180)[To read this article on Zacks.com click here.](https://www.zacks.com/stock/news/2315180/mediaalpha-inc-max-recently-broke-out-above-the-50-day-moving-average?cid=CS-NASDAQ-FT-tale_of_the_tape|50_day_moving_average_(yseop)-2315180)[Zacks Investment Research](https://www.zacks.com/) | MediaAlpha, Inc. (MAX) Recently Broke Out Above the 50-Day Moving Average | News | Zacks | Zacks Equity Research | 0.0552 | 14.5087 | 16.3317 | 16.4053 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.8286 | 15.7946 | 16.4638 | 16.5108 | 16.2369 | 17.271 | 18.2494 |
TLRY | Tilray Brands, Inc. | Health Care | Medicinal Chemicals and Botanical Products | https://www.nasdaq.com/articles/what-are-hottest-cannabis-stocks-right-now-3-top-picks | 2024-08-04 04:39:00 | CRON|Markets|CURLF | [InvestorPlace - Stock Market News, Stock Advice & Trading Tips](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral)[Cannabis stocks](https://investorplace.com/industries/healthcare/cannabis/?utm_source=Nasdaq&utm_medium=referral) have been through an extended period of depression. Overcapacity, regulatory headwinds, competition, and cash burn have contributed to the decline in the cannabis industry. However, markets react to extremes and I believe that [cannabis stocks](https://investorplace.com/industries/healthcare/cannabis/?utm_source=Nasdaq&utm_medium=referral) are undervalued. In addition to this, the regulatory environment is getting friendlier. Germany legalized recreational cannabis this year and I expect other European countries to follow suit. It’s also likely that cannabis will be reclassified as a Schedule III drug in the United States.It’s therefore a good time to buy cannabis stocks for multibagger returns. I must add here that cannabis companies are on a recovery path from a fundamental perspective.Several companies have achieved EBITDA breakeven and financial flexibility has improved. With ample scope for growth in a big addressable market, I expect revenue growth acceleration for some of the top cannabis companies. Let’s therefore talk about three cannabis stocks to buy and hold for the next few years. **Cronos Group (CRON)** [scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks](https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png) Source: Chokniti-Studio / Shutterstock.com** Cronos Group** (NASDAQ:** [CRON](http://www.nasdaq.com/symbol/cron)**) is among the best cannabis stocks to buy for multibagger returns in the long term. In the last 12 months, CRON stock has trended higher by 23%. However, the stock remains massively undervalued considering the fundamentals and growth potential. It’s worth noting that Cronos ended Q1 2024 with [cash and equivalents](https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-group-reports-2024-first-quarter-results) of $855 million. The company has high flexibility to pursue aggressive organic and acquisition driven growth. Cronos seems to be active on the geographical expansion front in the last 12 to 18 months.In early 2023, the cannabis company had a presence in Israel and Canada. Currently, Cronos has expanded into Germany, Australia, and the United Kingdom.The company’s [$51 million secured non-revolving credit facility](https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-group-announces-expansion-growco-fuel-global-growth) to GrowCo is a part of the global expansion effort. The financing will help in addressing the increased [global market](https://www.nasdaq.com/market-activity/indexes) demand for high-quality cannabis flower.With these factors in consideration, revenue growth acceleration is likely coupled with an improvement in the EBITDA margin. CRON stock therefore has significant upside potential. **Tilray Brands (TLRY)** [In this photo illustration, the Tilray Brands (TLRY) logo is displayed on a smartphone screen](https://investorplace.com/wp-content/uploads/2023/08/tlry1600-300x169.png) Source: rafapress / Shutterstock.com **Tilray Brands** (NASDAQ:** [TLRY](http://www.nasdaq.com/symbol/tlry)**) stock has remained subdued for an extended period. However, business developments are positive and I expect a strong rally from undervalued levels.Recently, Tilray reported results for Q4 2024 and [revenue increased by 25%](https://ir.tilray.com/news-releases/news-release-details/tilray-brands-reports-record-financial-results-achieves-26-net) on a year-on-year basis to $229.9 million. In my view, growth acceleration is likely in the next few years. My view is underscored by two factors.First, Tilray has been expanding aggressively in Europe and other emerging markets. The company’s medicinal cannabis business is likely to boost growth. Recently, the company was granted [approval](https://ir.tilray.com/news-releases/news-release-details/tilray-medical-granted-approval-introduce-third-medical-cannabis) for its third medicinal cannabis product in Portugal.Further, Tilray has [raised funds earlier this year](https://ir.tilray.com/news-releases/news-release-details/tilray-brands-announces-market-program-fund-strategic-and). The objective is to pursue organic or acquisition-driven growth in the U.S. once cannabis is reclassified as a Schedule III drug. A potential entry in the U.S. can boost growth. Therefore, with a diversified business, aggressive expansion, and margin improvement, TLRY stock is attractive. **Curaleaf Holdings (CURLF)** [Young green medicinal marijuana plant in a pot after a rain fall shallow depth of field with focus on leaf; cannabis stocks](https://investorplace.com/wp-content/uploads/2022/02/cannabis_1600_1793299462-300x169.png) Source: gvictoria / Shutterstock.com Amidst volatility, **Curaleaf Holdings**(OTCMKTS:** [CURLF](http://www.nasdaq.com/symbol/curlf)**) stock has been sideways in the last 12 months. I see this as a good buying opportunity and I expect CURLF stock to trend higher as industry headwinds wane.The first point to note is that Curaleaf has a presence in 17 states in the U.S. Even without federal-level legalization, the cannabis market is [expected to be worth](https://www.globenewswire.com/en/news-release/2023/03/22/2632475/0/en/U-S-Cannabis-Sales-Could-Total-71B-in-2030-Without-Federal-Legalization.html) $71 billion by 2030. With a big addressable market, I expect steady growth for Curaleaf in the coming years.Further, through organic growth and acquisitions, Curaleaf has been expanding its presence in Europe. The company believes that Europe’s [addressable market](https://filecache.investorroom.com/mr5ir_curaleaf/619/Curaleaf%20Investor%20Deck%204Q23_vF.pdf) is $248 billion. With investment in research-backed medicinal cannabis, Curaleaf is positioned to benefit.I must add here that for Q1 2024, the cannabis company [reported operating and free cash flow](https://ir.curaleaf.com/2024-05-09-Curaleaf-Reports-First-Quarter-2024-Results) of $46 million and $33 million respectively. As cash flows increase, Curaleaf will have higher financial flexibility to pursue aggressive expansion.On the date of publication, Faisal Humayun did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com [Publishing Guidelines.](https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&utm_medium=referral) On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Faisal Humayun is a senior research analyst with 12 years of industry experience in the field of credit research, equity research and financial modeling. Faisal has authored over 1,500 stock specific articles with focus on the technology, energy and commodities sector. **More From InvestorPlace** - [Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”](https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&eid=MKT802109&utm_source=Nasdaq&utm_medium=referral) The post [What Are the Hottest Cannabis Stocks Right Now? 3 Top Picks.](https://investorplace.com/2024/08/what-are-the-hottest-cannabis-stocks-right-now-3-top-picks/?utm_source=Nasdaq&utm_medium=referral) appeared first on [InvestorPlace](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral). | What Are the Hottest Cannabis Stocks Right Now? 3 Top Picks. | News | InvestorPlace | Faisal Humayun | 0.0552 | 2 | 1.95099 | 1.8544 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.81878 | 1.73964 | 1.77954 | 1.78632 | 1.77141 | 1.95215 | 1.72586 |
QURE | uniQure N.V. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/weekly-biotech-buzz-fgen-cuts-jobs-fda-oks-adaps-groundbreaking-cell-therapy-me-rebuffs | 2024-08-04 05:05:00 | ABUS|Markets|ZVRA|HLVX|AGIO|LLY|BIIB|ADAP|FGEN|PFE|VRTX|VIR|ME|MGNX | (RTTNews) - There seems to be no respite from job cuts as several companies announced workforce reductions this week as well. Meanwhile, on the research front, there was a mix of news: encouraging results emerged related to Alzheimer's drug Leqembi and antidiabetic medication Tirzepatide, while a prostate cancer drug trial unfortunately disappointed. In a significant development, the week also saw the approval of the first engineered cell therapy for a solid tumor. Let's delve into the news in detail. **Layoffs** FibroGen Inc. (FGEN) on Tuesday announced that it is reducing its headcount in the U.S. by approximately 75% as it prepares to shutter its once-promising Pamrevlumab development program. On July 30, 2024, the company's stock went into a freefall, plummeting nearly 48%, on news of its two late-stage trials of Pamrevlumab in patients with pancreatic cancer failing to meet the primary endpoint. FGEN closed Friday's trading at $0.42, down 8.94%. HilleVax Inc. (HLVX), a clinical-stage biopharmaceutical company developing novel vaccines, on Wednesday announced that it is reducing its workforce by approximately 41 employees, or roughly 40%, to rein in operating expenses. The lead drug candidate is HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 demonstrated statistically significant efficacy against moderate or severe AGE due to norovirus in a Phase 2b study in adults, dubbed NOR-211. However, in a phase IIb trial of HIL-214 in infants of approximately 5 months of age, dubbed [NEST-IN1](https://www.rttnews.com/3458582/hillevax-s-phase-2b-study-of-norovirus-vaccine-fails-stock-plunges-in-pre-market.aspx), the primary or secondary efficacy endpoints were not met. The company has decided to discontinue HIL-214's development for infants but will explore its potential application for adults. HLVX closed Friday's trading at $1.70, down 3.95%. Vir Biotechnology Inc. (VIR) on Thursday announced that it has initiated a strategic restructuring to focus on the highest value near-term opportunities. As part of the organizational realignment and optimization, the company has decided to phase out programs in influenza, COVID-19, and its T cell-based viral vector platform. This will also lead to a workforce reduction of approximately 25% or approximately 140 employees. VIR closed Friday's trading at $9.21, down 5.34%. uniQure N.V. (QURE), a gene therapy company, which recently sold its global [manufacturing facility in Lexington](https://www.rttnews.com/3457415/uniqure-to-sell-commercial-gene-therapy-manufacturing-facility-to-genezen-for-25-mln.aspx), Massachusetts to Contract Development and Manufacturing Organization Genezen, on Thursday announced major organizational changes. In an effort to conserve capital, streamline operations, and ensure sufficient cash resources to achieve multiple potentially meaningful value creating milestones, the company has decided to eliminate approximately 65% or 300 roles across the organization, inclusive of the sale of Lexington manufacturing facility. The restructuring is expected to be completed in the fourth quarter of 2024. QURE closed Friday's trading at $7.31, down 2.27%. Arbutus Biopharma Corp. (ABUS) is another company that is downsizing its workforce to streamline operations. The company on Thursday announced that it is ceasing all HBV discovery efforts and discontinuing its IM-PROVE III clinical trial, a phase IIa clinical trial evaluating lead drug candidate Imdusiran and nucleos(t) ide analogue (NA) therapy in combination with intermittent low doses of approved immune checkpoint inhibitor Durvalumab in patients with chronic HBV. This would result in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026. The company will now focus on phase 2b development of Imdusiran and another drug candidate AB-101, which is under a phase Ia/Ib trial for chronic HBV. ABUS closed Friday's trading at $3.73, down 1.97%. Pfizer Inc. (PFE), which recently pulled the plug on its investigational gene therapy Fordadistrogene movaparvovec for Duchenne muscular dystrophy, has decided to lay off 150 employees at its Sanford facility in Lee County. The company will also lay off 60 employees in its sterile injectable facility located in Rocky Mount in Nash County, according to reports. The company is targeting at least $4 billion in net cost savings by end of this year from a previously announced cost realignment program. A new cost reduction program announced by Pfizer in May of this year is expected to deliver savings of approximately $1.5 billion by the end of 2027. **FDA Spotlight** Vertex Pharmaceuticals Inc. (VRTX) on Tuesday announced that its New Drug Application for Suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor, has been accepted for priority review by the FDA. Suzetrigine is proposed for the treatment of moderate-to-severe acute pain. The FDA decision is due on January 30, 2025. If approved, Suzetrigine could become the first new class of medication for treating acute pain in more than two decades. VRTX closed Friday's trading at $494.46, down 2.24%. Adaptimmune Therapeutics plc (ADAP) on Thursday announced that Tecelra has been granted accelerated approval by the FDA for the treatment of advanced MAGE-A4+synovial sarcoma in adults with certain human leukocyte antigen (HLA) types who have received prior chemotherapy. Tecelra becomes the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. ADAP closed Friday's trading at $1.17, down 7.87%. Zevra Therapeutics Inc. (ZVRA) on Friday announced that an FDA panel has voted 11-5 recommending approval of its lead drug candidate Arimoclomol for the treatment of patients with Niemann-Pick disease type C (NPC). The FDA's final decision is due on September 21, 2024. Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder, marked by an inability of the body to transport cholesterol and other lipids within the cell, leading to an accumulation of these substances in various tissues and organs, including the brain. ZVRA closed Friday's trading at $6.30. **Deal or No Deal** 23andMe Holding Co. (ME) on Friday turned down the take-private proposal of Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of the company. Anne offered to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock. The Special Committee of the Board of Directors of the company, which reviewed the CEO's proposal, said it is "disappointed with the proposal for multiple reasons, including because it provides no premium to the closing price per share on Wednesday, July 31st, it lacks committed financing, and it is conditional in nature." ME closed Friday's trading at $0.38, down 0.26%. **Breakthroughs and Setbacks** Eisai Co. Ltd/Biogen Inc.'s (BIIB) Alzheimer's drug Leqembi showed improved cognition and function in patients with early Alzheimer's disease who received continuous treatment with the drug for over three years, revels a global phase III study, dubbed Clarity AD. Moreover, no additional safety concerns were observed with the extended Leqembi treatment over a three-year period. Leqembi was granted traditional FDA approval in July 2023 for use as an intravenous (IV) infusion in patients with mild cognitive impairment due to Alzheimer's disease and mild AD dementia. The company is also developing a subcutaneous injection formulation of Leqembi to enhance convenience for patients. It should be noted that last month, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended against approving Leqembi for Alzheimer's disease. The committee concluded that the drug's benefits do not outweigh the risks of serious side effects, such as brain swelling and potential bleeding, observed in patients who received the treatment. BIIB closed Friday's trading at $205.66, down 2.39%. Eli Lilly and Co.'s (LLY) antidiabetic medication Tirzepatide has shown to reduce the risk of heart failure outcomes - heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death - by 38% compared to placebo in a phase III trial in adults with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without type 2 diabetes. In the trial, [dubbed SUMMIT](https://www.rttnews.com/3465368/lilly-reports-positive-topline-results-from-summit-phase-3-study-of-tirzepatide.aspx), the drug also significantly improved heart failure symptoms and physical limitations and led to 15.7% weight loss in a combined population of people with and without type 2 diabetes. Tirzepatide was approved by the FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound for adults with obesity or those who are overweight who also have a weight-related comorbid condition on November 8, 2023. Both Mounjaro and Zepbound are approved as an adjunct to diet and exercise. LLY closed Friday's trading at $804.46, down 3.36%. Agios Pharmaceuticals Inc.'s (AGIO) blood disorder drug Pyrukynd has failed to meet the primary endpoint of transfusion reduction response in a phase III study in children aged 1 to less than 18 years with pyruvate kinase (PK) deficiency who are regularly transfused, dubbed ACTIVATE-KidsT. Although the primary endpoint was not met, the results were clinically meaningful, according to the company. A phase III trial of Pyrukynd in children with PK deficiency who are not regularly transfused, dubbed ACTIVATE-kids, is ongoing, with topline data anticipated in 2025. Pyrukynd is approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great Britain. AGIO closed Friday's trading at $43.96, down 1.21%. Shares of MacroGenics Inc. (MGNX) have been on a downward spiral since the company provided an update on its TAMARACK trial in May of this year. TAMARACK is a phase II study evaluating the company's investigational drug Vobra duo in metastatic castration-resistant prostate cancer. On May 9, 2024, the company revealed that a total of five patient deaths occurred in the TAMARACK study. After a review of accumulated study data, MacroGenics in late July, agreed with the study's Independent Data Monitoring Committee's (IDMC) recommendation that study treatment should be discontinued for the remaining metastatic castration-resistant prostate cancer study participants who potentially could have received additional doses. MGNX closed Friday's trading at $3.83, down 4.25%. | Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid | News | RTTNews | RTTNews.com | 0.0552 | 7.60988 | 7.61246 | 7.4411 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.2064 | 7.12848 | 7.43127 | 7.64684 | 7.15986 | 6.65452 | 5.87336 |
ABUS | Arbutus Biopharma Corporation | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/weekly-biotech-buzz-fgen-cuts-jobs-fda-oks-adaps-groundbreaking-cell-therapy-me-rebuffs | 2024-08-04 05:05:00 | Markets|ZVRA|HLVX|AGIO|LLY|BIIB|ADAP|FGEN|PFE|VRTX|VIR|ME|MGNX|QURE | (RTTNews) - There seems to be no respite from job cuts as several companies announced workforce reductions this week as well. Meanwhile, on the research front, there was a mix of news: encouraging results emerged related to Alzheimer's drug Leqembi and antidiabetic medication Tirzepatide, while a prostate cancer drug trial unfortunately disappointed. In a significant development, the week also saw the approval of the first engineered cell therapy for a solid tumor. Let's delve into the news in detail. **Layoffs** FibroGen Inc. (FGEN) on Tuesday announced that it is reducing its headcount in the U.S. by approximately 75% as it prepares to shutter its once-promising Pamrevlumab development program. On July 30, 2024, the company's stock went into a freefall, plummeting nearly 48%, on news of its two late-stage trials of Pamrevlumab in patients with pancreatic cancer failing to meet the primary endpoint. FGEN closed Friday's trading at $0.42, down 8.94%. HilleVax Inc. (HLVX), a clinical-stage biopharmaceutical company developing novel vaccines, on Wednesday announced that it is reducing its workforce by approximately 41 employees, or roughly 40%, to rein in operating expenses. The lead drug candidate is HIL-214, a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 demonstrated statistically significant efficacy against moderate or severe AGE due to norovirus in a Phase 2b study in adults, dubbed NOR-211. However, in a phase IIb trial of HIL-214 in infants of approximately 5 months of age, dubbed [NEST-IN1](https://www.rttnews.com/3458582/hillevax-s-phase-2b-study-of-norovirus-vaccine-fails-stock-plunges-in-pre-market.aspx), the primary or secondary efficacy endpoints were not met. The company has decided to discontinue HIL-214's development for infants but will explore its potential application for adults. HLVX closed Friday's trading at $1.70, down 3.95%. Vir Biotechnology Inc. (VIR) on Thursday announced that it has initiated a strategic restructuring to focus on the highest value near-term opportunities. As part of the organizational realignment and optimization, the company has decided to phase out programs in influenza, COVID-19, and its T cell-based viral vector platform. This will also lead to a workforce reduction of approximately 25% or approximately 140 employees. VIR closed Friday's trading at $9.21, down 5.34%. uniQure N.V. (QURE), a gene therapy company, which recently sold its global [manufacturing facility in Lexington](https://www.rttnews.com/3457415/uniqure-to-sell-commercial-gene-therapy-manufacturing-facility-to-genezen-for-25-mln.aspx), Massachusetts to Contract Development and Manufacturing Organization Genezen, on Thursday announced major organizational changes. In an effort to conserve capital, streamline operations, and ensure sufficient cash resources to achieve multiple potentially meaningful value creating milestones, the company has decided to eliminate approximately 65% or 300 roles across the organization, inclusive of the sale of Lexington manufacturing facility. The restructuring is expected to be completed in the fourth quarter of 2024. QURE closed Friday's trading at $7.31, down 2.27%. Arbutus Biopharma Corp. (ABUS) is another company that is downsizing its workforce to streamline operations. The company on Thursday announced that it is ceasing all HBV discovery efforts and discontinuing its IM-PROVE III clinical trial, a phase IIa clinical trial evaluating lead drug candidate Imdusiran and nucleos(t) ide analogue (NA) therapy in combination with intermittent low doses of approved immune checkpoint inhibitor Durvalumab in patients with chronic HBV. This would result in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026. The company will now focus on phase 2b development of Imdusiran and another drug candidate AB-101, which is under a phase Ia/Ib trial for chronic HBV. ABUS closed Friday's trading at $3.73, down 1.97%. Pfizer Inc. (PFE), which recently pulled the plug on its investigational gene therapy Fordadistrogene movaparvovec for Duchenne muscular dystrophy, has decided to lay off 150 employees at its Sanford facility in Lee County. The company will also lay off 60 employees in its sterile injectable facility located in Rocky Mount in Nash County, according to reports. The company is targeting at least $4 billion in net cost savings by end of this year from a previously announced cost realignment program. A new cost reduction program announced by Pfizer in May of this year is expected to deliver savings of approximately $1.5 billion by the end of 2027. **FDA Spotlight** Vertex Pharmaceuticals Inc. (VRTX) on Tuesday announced that its New Drug Application for Suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor, has been accepted for priority review by the FDA. Suzetrigine is proposed for the treatment of moderate-to-severe acute pain. The FDA decision is due on January 30, 2025. If approved, Suzetrigine could become the first new class of medication for treating acute pain in more than two decades. VRTX closed Friday's trading at $494.46, down 2.24%. Adaptimmune Therapeutics plc (ADAP) on Thursday announced that Tecelra has been granted accelerated approval by the FDA for the treatment of advanced MAGE-A4+synovial sarcoma in adults with certain human leukocyte antigen (HLA) types who have received prior chemotherapy. Tecelra becomes the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults. ADAP closed Friday's trading at $1.17, down 7.87%. Zevra Therapeutics Inc. (ZVRA) on Friday announced that an FDA panel has voted 11-5 recommending approval of its lead drug candidate Arimoclomol for the treatment of patients with Niemann-Pick disease type C (NPC). The FDA's final decision is due on September 21, 2024. Niemann-Pick disease type C (NPC) is an ultra-rare, progressive, and neurodegenerative lysosomal storage disorder, marked by an inability of the body to transport cholesterol and other lipids within the cell, leading to an accumulation of these substances in various tissues and organs, including the brain. ZVRA closed Friday's trading at $6.30. **Deal or No Deal** 23andMe Holding Co. (ME) on Friday turned down the take-private proposal of Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of the company. Anne offered to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock. The Special Committee of the Board of Directors of the company, which reviewed the CEO's proposal, said it is "disappointed with the proposal for multiple reasons, including because it provides no premium to the closing price per share on Wednesday, July 31st, it lacks committed financing, and it is conditional in nature." ME closed Friday's trading at $0.38, down 0.26%. **Breakthroughs and Setbacks** Eisai Co. Ltd/Biogen Inc.'s (BIIB) Alzheimer's drug Leqembi showed improved cognition and function in patients with early Alzheimer's disease who received continuous treatment with the drug for over three years, revels a global phase III study, dubbed Clarity AD. Moreover, no additional safety concerns were observed with the extended Leqembi treatment over a three-year period. Leqembi was granted traditional FDA approval in July 2023 for use as an intravenous (IV) infusion in patients with mild cognitive impairment due to Alzheimer's disease and mild AD dementia. The company is also developing a subcutaneous injection formulation of Leqembi to enhance convenience for patients. It should be noted that last month, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended against approving Leqembi for Alzheimer's disease. The committee concluded that the drug's benefits do not outweigh the risks of serious side effects, such as brain swelling and potential bleeding, observed in patients who received the treatment. BIIB closed Friday's trading at $205.66, down 2.39%. Eli Lilly and Co.'s (LLY) antidiabetic medication Tirzepatide has shown to reduce the risk of heart failure outcomes - heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death - by 38% compared to placebo in a phase III trial in adults with heart failure with preserved ejection fraction (HFpEF) and obesity, with or without type 2 diabetes. In the trial, [dubbed SUMMIT](https://www.rttnews.com/3465368/lilly-reports-positive-topline-results-from-summit-phase-3-study-of-tirzepatide.aspx), the drug also significantly improved heart failure symptoms and physical limitations and led to 15.7% weight loss in a combined population of people with and without type 2 diabetes. Tirzepatide was approved by the FDA as Mounjaro for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound for adults with obesity or those who are overweight who also have a weight-related comorbid condition on November 8, 2023. Both Mounjaro and Zepbound are approved as an adjunct to diet and exercise. LLY closed Friday's trading at $804.46, down 3.36%. Agios Pharmaceuticals Inc.'s (AGIO) blood disorder drug Pyrukynd has failed to meet the primary endpoint of transfusion reduction response in a phase III study in children aged 1 to less than 18 years with pyruvate kinase (PK) deficiency who are regularly transfused, dubbed ACTIVATE-KidsT. Although the primary endpoint was not met, the results were clinically meaningful, according to the company. A phase III trial of Pyrukynd in children with PK deficiency who are not regularly transfused, dubbed ACTIVATE-kids, is ongoing, with topline data anticipated in 2025. Pyrukynd is approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great Britain. AGIO closed Friday's trading at $43.96, down 1.21%. Shares of MacroGenics Inc. (MGNX) have been on a downward spiral since the company provided an update on its TAMARACK trial in May of this year. TAMARACK is a phase II study evaluating the company's investigational drug Vobra duo in metastatic castration-resistant prostate cancer. On May 9, 2024, the company revealed that a total of five patient deaths occurred in the TAMARACK study. After a review of accumulated study data, MacroGenics in late July, agreed with the study's Independent Data Monitoring Committee's (IDMC) recommendation that study treatment should be discontinued for the remaining metastatic castration-resistant prostate cancer study participants who potentially could have received additional doses. MGNX closed Friday's trading at $3.83, down 4.25%. | Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid | News | RTTNews | RTTNews.com | 0.0552 | 3.81029 | 3.77128 | 3.73235 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.34955 | 3.33217 | 3.59625 | 3.65411 | 3.55145 | 3.76534 | 3.89726 |
ALT | Altimmune, Inc. | Health Care | Biotechnology: Pharmaceutical Preparations | https://www.nasdaq.com/articles/2-small-cap-stocks-under-20-over-220-upside-potential | 2024-08-04 11:17:00 | Stocks|LLY|MRK|EYPT|NVO | The biopharmaceutical industry is thriving, with breakthroughs in treating obesity, metabolic dysfunction-associated steatohepatitis (MASH), and retinal disease. While giants like Eli Lilly and Company [(LLY)](https://www.nasdaq.com/market-activity/stocks/lly), Novo Nordisk [(NVO)](https://www.nasdaq.com/market-activity/stocks/nvo), and Merck & Co., Inc. [(MRK)](https://www.nasdaq.com/market-activity/stocks/mrk) dominate the headlines, it's the clinical-stage biopharma companies trading under $20 that are more often associated with game-changing investment returns.EyePoint Pharmaceuticals, Inc. [(EYPT)](https://www.nasdaq.com/market-activity/stocks/eypt) and Altimmune, Inc. [(ALT)](https://www.nasdaq.com/market-activity/stocks/alt) are two small [biotech stocks](https://www.barchart.com/investing-ideas/biotech/stocks?viewName=performance) that Wall Street analysts expect to rally more than 200% within the next year. These types of early-stage, niche market players often carry high volatility and risk, but equally high potential. For investors ready to embrace the risk, these stocks might just be the ticket to substantial gains. ****Stock #1: EyePoint Pharmaceuticals****Incorporated in 1987, Watertown, Massachusetts-headquartered EyePoint Pharmaceuticals, Inc. [(EYPT)](https://www.nasdaq.com/market-activity/stocks/eypt) is a clinical-stage biopharmaceutical company engaging in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.The company harnesses its cutting-edge Durasert E technology for sustained intraocular drug delivery. Its lead candidate, DURAVYU, blends vorolanib, a potent VEGF inhibitor, with Durasert E for lasting impact. EyePoint's innovative pipeline, including EYP-2301 and razuprotafib, offers promising solutions for serious retinal conditions.With a market cap of $475.5 million, EyePoint Pharmaceuticals is a small-cap player. Its shares are typically volatile for a smaller biotech, down 62.1% on a YTD basis - even as EYPT still trades [54% above its 52-week low](https://www.nasdaq.com/market-activity/stocks/eypt) of $5.67, set last October.[Image](https://barchart-news-media-prod.aws.barchart.com/EXCLSV/6ca23f73a2fbbca8735b8336c8ce3f42/ad_4nxdjfbgrabsjqakj73somm3-qwkpk8gfzfnqjntgsfow9mmqe8tu_qrvcrwy6wzl3ozvfv52hmt20lpohlwkzmpzjjixtnkdkinn0sr1uucxmmpcea-kf6jtxpuyzfbrxzulf-os-pfw6vhmg6wmn_7ptya3%3Fkey%3D3hkovh0v23ibeahu8eabmq) [www.barchart.com](https://www.nasdaq.com/market-activity/stocks/eypt/advanced-charting) Shares of EyePoint Pharmaceuticals soared [9.6% in a single session](https://www.nasdaq.com/market-activity/stocks/eypt) after the biotech company posted [Q1 results on May 8](https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-first-quarter-2024-financial). Revenue jumped 52.1% annually to $11.7 million, smashing expectations by 27.9%. The quarterly loss per share shrank slightly to $0.55.EyePoint wrapped up the quarter with $299.3 million in cash and investments, securing a cash runway through the upcoming Phase 3 DURAVYU trials for wet AMD, expected in 2026. As the company gears up to report [Q2 earnings results](https://www.barchart.com/stocks/earnings-dividends) on August 7, analysts predict EyePoint's loss per share to shrink 9.8% year over year to $0.55.EYPT has a unanimous “Strong Buy” rating from all nine analysts covering the stock. The [average analyst price target](https://www.nasdaq.com/market-activity/stocks/eypt/analyst-research) for EyePoint is $35.38, indicating a massive potential upside of 304%.[Image](https://barchart-news-media-prod.aws.barchart.com/EXCLSV/6ca23f73a2fbbca8735b8336c8ce3f42/ad_4nxerupgjq6bdt8ykqmid6pccbncaqtmfxklit077m3orjsgjmuqppqigflq-qvu6d6f16ie4wyjukns3abbwqsohmhptlxq8xocukyohn2bhfeomj4ayvvvsrlypjhqt6w2dsfsmbm4sij-nsvl5vvhjc0em%3Fkey%3D3hkovh0v23ibeahu8eabmq) [www.barchart.com](https://www.nasdaq.com/market-activity/stocks/eypt/analyst-research)****Stock #2: Altimmune****Founded in 1997, Altimmune, Inc. [(ALT)](https://www.nasdaq.com/market-activity/stocks/alt) is a clinical-stage biopharma company with a market cap of $431.8 million. Based in Gaithersburg, Maryland, it focuses on developing treatments for obesity, and recently wound down its liver disease operations. Altimmune's lead product, pemvidutide, is a [GLP-1/glucagon dual receptor agonist](https://www.barchart.com/story/news/27128450/3-reasons-why-altimmune-stock-could-be-the-next-viking-therapeutics) in Phase 2 trials.The small-cap stock is down 46.7% on a YTD basis, paring its 52-week return to [96.7%](https://www.nasdaq.com/market-activity/stocks/alt).[Image](https://barchart-news-media-prod.aws.barchart.com/EXCLSV/6ca23f73a2fbbca8735b8336c8ce3f42/ad_4nxfs-qzvkfg0q3leodcljjdab9hu872_znzf-mponkdb6wwbm2skazx_16bvitl32mhanpmw_xlh_u0eo_q1qxrkua7hyd8cjuvizovgycgcw4bcu1ugjyrpqzoml1pimsyaf4ccp-o0wbinftu0xpljfsug%3Fkey%3D3hkovh0v23ibeahu8eabmq) [www.barchart.com](https://www.nasdaq.com/market-activity/stocks/alt/advanced-charting) On May 9, Altimmune reported its [Q1 earnings results](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2024-financial-results-and), and the pre-revenue company managed to narrow its loss to $0.34 per share, even as it ramped up R&D expenses year over year. In March 2024, Altimmune unveiled promising data from the Phase 2 MOMENTUM trial of pemvidutide for obesity, showing impressive weight loss while preserving lean mass. The company is gearing up for an End-of-Phase 2 meeting with the FDA in late Q3 2024 and will present comprehensive MOMENTUM data, which could be the next catalyst for the stock. Meanwhile, the Phase 2b IMPACT trial for MASH continues, with results expected in Q1 2025.Altimmune ended Q1 with $182.1 million in cash and no long-term debt. The company is expected to report its [Q2 earnings results](https://www.barchart.com/stocks/earnings-dividends) on Thursday, August 8. Analysts tracking Altimmune expect its loss per share for the quarter to reach $0.34.ALT stock has a consensus “Strong Buy” rating overall. Out of the seven analysts offering recommendations, five suggest a “Strong Buy,” and the remaining two advise a “Hold” rating.[Image](https://barchart-news-media-prod.aws.barchart.com/EXCLSV/6ca23f73a2fbbca8735b8336c8ce3f42/ad_4nxdyzeq-14wi0vwividngjr80hvgnyctsc5vjacr4qfnlgzjrmsrimumswlo8sgf-y8vp9taym47wlusrwr--vi7qfjstagvzlgeo38zifeabry8iohmu4ooqps9lxwvf9wmq2-owwfefonqzvqn2i3saxc%3Fkey%3D3hkovh0v23ibeahu8eabmq) [www.barchart.com](https://www.nasdaq.com/market-activity/stocks/alt/analyst-research) The [average analyst price target of $19.71](https://www.nasdaq.com/market-activity/stocks/alt/analyst-research) suggests that ALT stock has 228.5% upside potential from the current price levels. On the date of publication, [Sristi Suman Jayaswal](https://www.barchart.com/news/authors/398/sristi-suman-jayaswal) did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy [here](https://www.barchart.com/terms#disclosure). | 2 Small-Cap Stocks Under $20 With Over 220% Upside Potential | News | Barchart | Sristi Suman Jayaswal | 0.0552 | 6.33 | 5.85357 | 6.03501 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.83252 | 5.73166 | 5.90997 | 5.68 | 6.56893 | 6.76184 | 6.37 |
GTX | Garrett Motion Inc. | Consumer Discretionary | Auto Parts:O.E.M. | https://www.nasdaq.com/articles/3-undervalued-stocks-youve-never-heard | 2024-08-04 18:21:00 | GCT|Markets|IMAX | [InvestorPlace - Stock Market News, Stock Advice & Trading Tips](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral) Investing in [undervalued stocks](https://investorplace.com/stock-types/undervalued-stocks/?utm_source=Nasdaq&utm_medium=referral) gives investors an edge in capitalizing on companies with high growth potential. Listing these stocks involves scanning the fundamentals, which helps mark potential the market might overlook. Indeed, fundamentals like top-line growth, profit margins, and strategic initiatives reflect a company’s true value. Here, the focus is on three undervalued stocks. To begin with, the first company has demonstrated significant growth in its core business by expanding its global network and increasing system installations. Strategic partnerships and a robust content pipeline further bolster its market position, making it a strong candidate for investment.Meanwhile, the second company operates a rapidly growing marketplace. This can be observed in a high increase in Gross Merchandise Value (GMV) and active third-party (3P) sellers. This growth is accompanied by a rising number of active buyers and a higher average spend per buyer, which indicates its expanding and engaged customer base. Finally, the third company is making significant strides in zero-emission technologies. It is securing contracts for large fuel cell applications and advancing its high-speed motor technologies.In short, these innovations highlight its strategic focus on the green technology sector, positioning it for high growth. **Imax (IMAX)** [the exterior of an Imax theater](https://investorplace.com/wp-content/uploads/2020/03/imax-stock-1-300x169.jpg) Source: imageAllan / Shutterstock.com** Imax** (NYSE: [IMAX](http://www.nasdaq.com/symbol/imax)) focuses on immersive cinematic systems. The company experienced installation growth of [20% year-over-year (YoY)](https://imaxcorporation.gcs-web.com/node/25231/pdf) in Q2 2024. It installed 24 systems, up from 20 in Q2 2023, with total installations in H1 2024 reaching 39, a 34% increase from 2023. Further, Imax signed agreements for 87 new (or upgraded) systems in Q2 2024, representing an 89% increase from the 46 signings in Q2 2023. The company ended Q2 2024 with a backlog of over 500 systems. It raised its 2024 installation guidance to [130-150 systems](https://seekingalpha.com/article/4706812-imax-corporation-imax-q2-2024-earnings-call-transcript). This is up from the previous range of 120-150 systems. Moreover, a significant deal with Wanda Film includes up to [123 new IMAX systems](https://imaxcorporation.gcs-web.com/node/25231/pdf) in China. This deal is Imax’s largest exhibition agreement in five years, aiming to expand Imax’s presence in China’s lucrative market. Many upgraded systems will be in Tier 1 cities, enhancing revenue potential. Imax’s film slate through 2026 includes at least 14 films shot with IMAX cameras. Significant titles include Mission Impossible 8 and Avatar 3. Indeed, this pipeline is expected to drive box office success and system utilization.Imax’s strategic moves and partnerships strengthen its position among undervalued stocks. **GigaCloud (GCT)** [A large amount of SALE signs. undervalued stocks to buy. underdog stocks set for turnaround. Most Undervalued S&P 500 Stocks to Buy in April](https://investorplace.com/wp-content/uploads/2021/09/undervalued-stocks-300x169.jpg) Source: akamakis / Shutterstock.com** GigaCloud** (NASDAQ: [GCT](http://www.nasdaq.com/symbol/gct)) operates a growing marketplace with solid expansion. The GMV surged by 64% YoY, [hitting $907.7 million](https://investors.gigacloudtech.com/news-releases/news-release-details/gigacloud-technology-inc-announces-first-quarter-ended-march-31) for the 12 months ending March 2024. This was up from $553.5 million the previous year. The growth reflects the increased scale and transaction volume in GigaCloud’s marketplace. Moreover, 3P Seller GMV jumped by 71.8% to $489.9 million. It was $285.2 million a year ago. This segment now makes up 54% of total GMV, up from 51.5%. The rise in 3P seller GMV indicates more participation from third-party sellers.Further, active 3P sellers [grew by 43.7%](https://investors.gigacloudtech.com/news-releases/news-release-details/gigacloud-technology-inc-announces-first-quarter-ended-march-31), reaching 865 compared to 602 in the previous year. This increase highlights GigaCloud’s appeal to a broader range of suppliers. Active buyers also rose by 29.1% to 5,493 from 4,255. The average spend per active buyer increased by [ 27% to $165,239](https://investors.gigacloudtech.com/static-files/bf936436-18d9-4ea0-a476-f2eb921cc0dd). The growth of active buyers and spending shows a more engaged customer base. This is essential for sustaining marketplace growth and profitability. GigaCloud’s strong performance positions it as a notable presence among undervalued stocks. **Garrett Motion (GTX)** [Coins for Undervalued Value Stocks](https://investorplace.com/wp-content/uploads/2010/07/7640547-chart-golden-coins-300x223.jpg) Source: [Via iStock](http://www.istockphoto.com/)**Garrett Motion** (NASDAQ: [GTX](http://www.nasdaq.com/symbol/gtx)) develops zero-emission technologies with significant investments. The company has secured its [first series production contract ](https://seekingalpha.com/article/4706607-garrett-motion-inc-gtx-q2-2024-earnings-call-transcript) for a large fuel cell application. This contract is aimed at the Commercial Vehicle and Industrial segments and underscores Garrett’s growing presence in zero-emission technology. Garrett has a broad and mature portfolio of fuel cell compressors. Indeed, this positions the company to capture growth in this emerging market. Garrett has advanced high-speed motor technologies for commercial vehicles and has achieved several predevelopment awards for these technologies.Additionally, the company’s progress in E-Powertrain technology shows its innovation capabilities. Garrett has also won [two additional predevelopment contracts](https://seekingalpha.com/article/4706607-garrett-motion-inc-gtx-q2-2024-earnings-call-transcript). These contracts are for high-power centrifugal compressors used in commercial vehicles. Moreover, Garrett’s investments and new contracts reflect its strategic focus on green technology. The company repaid $186 million of its Euro-denominated Term Loan B. This reduced its total debt from [$1,683 million to $1,497 million.](https://investors.garrettmotion.com/node/11641/pdf) Further, Garrett repaid $985 million in term loans early. As of June 30, 2024, the company had a stronger liquidity position of $698 million. This debt reduction highlights Garrett’s effective capital management. Therefore, Garrett Motion is a top undervalued stock due to its green tech advancements and debt reduction. On the date of publication, Yiannis Zourmpanos did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com [Publishing Guidelines.](https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&utm_medium=referral) On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Yiannis Zourmpanos is the founder of Yiazou Capital Research, a stock-market research platform designed to elevate the due diligence process through in-depth business analysis. **More From InvestorPlace** - [Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”](https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&eid=MKT802109&utm_source=Nasdaq&utm_medium=referral) The post [3 Undervalued Stocks You’ve Never Heard Of](https://investorplace.com/2024/08/3-undervalued-stocks-youve-never-heard-of/?utm_source=Nasdaq&utm_medium=referral) appeared first on [InvestorPlace](https://investorplace.com/?utm_source=Nasdaq&utm_medium=referral). | 3 Undervalued Stocks You’ve Never Heard Of | News | InvestorPlace | Yiannis Zourmpanos | 0.0552 | 8.93467 | 8.42388 | 8.14271 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 8.00873 | 7.99214 | 8.04022 | 7.97198 | 8.05661 | 8.07221 | 8.34751 |
ML | MoneyLion Inc. | Finance | Finance: Consumer Services | https://www.nasdaq.com/articles/valideas-top-information-technology-stocks-based-motley-fool-8-4-2024 | 2024-08-04 18:30:00 | NN|Markets|CLBT|CNXN|AVPT | The following are the top rated Information Technology stocks according to Validea's [Small-Cap Growth Investor](https://www.validea.com/small-cap-growth-investor-portfolio/motley-fool) model based on the published strategy of [Motley Fool](https://www.validea.com/motley-fool). This strategy looks for small cap growth stocks with solid fundamentals and strong price performance. **NEXTNAV INC ([NN](https://www.nasdaq.com/market-activity/stocks/NN)))** is a small-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Motley Fool is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**NextNav Inc. (NextNav) is engaged in delivering positioning, navigation, and timing (PNT) solutions that overcome the limitations of the existing space-based global positioning system (GPS). NextNav delivers differentiated PNT solutions through its network-based Pinnacle and TerraPoiNT solutions. Pinnacle is its z-axis service, a vertical positioning network to cover the entire metropolitan area. Its Pinnacle system provides accurate altitude service to any device with a barometric pressure sensor, including most off-the-shelf Android and iOS smartphones, appropriately specified internet of things (IOT) devices, as well as vehicles and other equipment. TerraPoiNT system is a terrestrial-based, encrypted network designed to overcome the limitations inherent in the space-based nature of GPS. It also provides advanced geolocation solutions to IoT modem and digital signal processor vendors and end IoT users. Its customers include wireless carriers, applications developers, and others.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & PASS \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & FAIL \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of NEXTNAV INC [NN Guru Analysis](https://www.validea.com/guru-analysis/nn)[NN Fundamental Analysis](https://www.validea.com/factor-report/nn)**PC CONNECTION, INC. ([CNXN](https://www.nasdaq.com/market-activity/stocks/CNXN)))** is a small-cap growth stock in the Computer Hardware industry. The rating according to our strategy based on Motley Fool is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**PC Connection, Inc. delivers custom-configured computer systems overnight from its ISO 9001:2015 certified technical configuration lab at its distribution center in Wilmington, Ohio. The Company provides a range of information technology (IT) solutions, from the desktop to the cloud, including computer systems, data center solutions, software and peripheral equipment, networking communication, and other products and accessories, which the Company purchases from manufacturers, distributors and other suppliers. The Company operates through three segments: Connection Enterprise Solutions, Connection Business Solutions and Connection Public Sector Solutions. Connection Enterprise Solutions segment is engaged in serving large enterprise customers. Connection Business Solutions segment is engaged in serving small to medium-sized businesses (SMBs). Connection Public Sector Solutions segment is engaged in serving federal, state, and local government and educational institutions. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & FAIL \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & PASS \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline INVENTORY TO SALES: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & FAIL \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & PASS \\ \hline \end{table} Detailed Analysis of PC CONNECTION, INC.[CNXN Guru Analysis](https://www.validea.com/guru-analysis/cnxn)[CNXN Fundamental Analysis](https://www.validea.com/factor-report/cnxn)**MONEYLION INC ([ML](https://www.nasdaq.com/market-activity/stocks/ML)))** is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**MoneyLion Inc. is a financial technology company. The Company designs and offers modern personal finance products, tools and features and curates money-related content that delivers actionable insights and guidance to its users. Through its Consumer platform, accessible through the free-to-download MoneyLion mobile application and online at www.moneylion.com, it offers its integrated core suite of financial products and services to make banking, borrowing and investing accessible to everyone. Its financial products and services include RoarMoney, Instacash, Membership Programs, MoneyLion Investing, MoneyLion Crypto and Round Ups. Its marketplace solutions provide valuable distribution, acquisition, growth and monetization channels for its partners. MoneyLion Investing is an online investment account that offers access to separately managed accounts invested based on model exchange-traded fund (ETF) portfolios. MoneyLion Crypto is an online cryptocurrency account.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & FAIL \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of MONEYLION INC [ML Guru Analysis](https://www.validea.com/guru-analysis/ml)[ML Fundamental Analysis](https://www.validea.com/factor-report/ml)**CELLEBRITE DI LTD ([CLBT](https://www.nasdaq.com/market-activity/stocks/CLBT)))** is a mid-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**Cellebrite DI Ltd is an Israel-based software developer. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Platform enables users to collect, view, analyse and manage digital data throughout the entire investigation cycle. The Company's platform improves the investigation process for public defenders, police departments, state departments, armed services, legal and corporate security; this leads to an accelerated speed of investigations and increased crime clearance rates.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & PASS \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & FAIL \\ \hline R&D AS A PERCENTAGE OF SALES: & FAIL \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline INVENTORY TO SALES: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of CELLEBRITE DI LTD [CLBT Guru Analysis](https://www.validea.com/guru-analysis/clbt)[CLBT Fundamental Analysis](https://www.validea.com/factor-report/clbt)**AVEPOINT INC ([AVPT](https://www.nasdaq.com/market-activity/stocks/AVPT)))** is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**AvePoint, Inc. provides a cloud-native software platform that organizations rely on to optimize information technology (IT) operations, manage critical data and secure the digital workplace. The Company's AvePoint Confidence Platform delivers a set of software-as-a-service (SaaS) solutions, empowering users in a variety of technology roles, including IT operations, development operations and cybersecurity to monitor and secure the digital workplace. Built on top of platform-as-a-service (PaaS) architecture, the AvePoint Confidence Platform offers modularity and combines cloud services architecture with industry-specific functionality to address operational challenges and the ongoing management of data, as organizations leverage a variety of third-party cloud vendors. The AvePoint Confidence Platform, and the applications that it powers, is organized into three interconnected suites of functionality, which include The Control Suite, The Resilience Suite and The Modernization Suite.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & FAIL \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of AVEPOINT INC [AVPT Guru Analysis](https://www.validea.com/guru-analysis/avpt)[AVPT Fundamental Analysis](https://www.validea.com/factor-report/avpt)[Motley Fool Portfolio](https://www.validea.com/motley-fool)**About Motley Fool**: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services. **About Validea**: Validea is an [investment research](https://www.nasdaq.com/market-activity) service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, [click here](http://www.validea.com/) | Validea's Top Information Technology Stocks Based On Motley Fool - 8/4/2024 | News | Validea | John Reese | 0.0552 | 67.7436 | 64.3799 | 2.86277 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 57.1884 | 40.5888 | 61.0201 | 48.6147 | 44.3174 | 43.8757 | 46.1454 |
NN | NextNav Inc. | Industrials | Industrial Machinery/Components | https://www.nasdaq.com/articles/valideas-top-information-technology-stocks-based-motley-fool-8-4-2024 | 2024-08-04 18:30:00 | Markets|ML|CLBT|CNXN|AVPT | The following are the top rated Information Technology stocks according to Validea's [Small-Cap Growth Investor](https://www.validea.com/small-cap-growth-investor-portfolio/motley-fool) model based on the published strategy of [Motley Fool](https://www.validea.com/motley-fool). This strategy looks for small cap growth stocks with solid fundamentals and strong price performance. **NEXTNAV INC ([NN](https://www.nasdaq.com/market-activity/stocks/NN)))** is a small-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Motley Fool is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**NextNav Inc. (NextNav) is engaged in delivering positioning, navigation, and timing (PNT) solutions that overcome the limitations of the existing space-based global positioning system (GPS). NextNav delivers differentiated PNT solutions through its network-based Pinnacle and TerraPoiNT solutions. Pinnacle is its z-axis service, a vertical positioning network to cover the entire metropolitan area. Its Pinnacle system provides accurate altitude service to any device with a barometric pressure sensor, including most off-the-shelf Android and iOS smartphones, appropriately specified internet of things (IOT) devices, as well as vehicles and other equipment. TerraPoiNT system is a terrestrial-based, encrypted network designed to overcome the limitations inherent in the space-based nature of GPS. It also provides advanced geolocation solutions to IoT modem and digital signal processor vendors and end IoT users. Its customers include wireless carriers, applications developers, and others.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & PASS \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & FAIL \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of NEXTNAV INC [NN Guru Analysis](https://www.validea.com/guru-analysis/nn)[NN Fundamental Analysis](https://www.validea.com/factor-report/nn)**PC CONNECTION, INC. ([CNXN](https://www.nasdaq.com/market-activity/stocks/CNXN)))** is a small-cap growth stock in the Computer Hardware industry. The rating according to our strategy based on Motley Fool is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**PC Connection, Inc. delivers custom-configured computer systems overnight from its ISO 9001:2015 certified technical configuration lab at its distribution center in Wilmington, Ohio. The Company provides a range of information technology (IT) solutions, from the desktop to the cloud, including computer systems, data center solutions, software and peripheral equipment, networking communication, and other products and accessories, which the Company purchases from manufacturers, distributors and other suppliers. The Company operates through three segments: Connection Enterprise Solutions, Connection Business Solutions and Connection Public Sector Solutions. Connection Enterprise Solutions segment is engaged in serving large enterprise customers. Connection Business Solutions segment is engaged in serving small to medium-sized businesses (SMBs). Connection Public Sector Solutions segment is engaged in serving federal, state, and local government and educational institutions. The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & FAIL \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & PASS \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline INVENTORY TO SALES: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & FAIL \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & PASS \\ \hline \end{table} Detailed Analysis of PC CONNECTION, INC.[CNXN Guru Analysis](https://www.validea.com/guru-analysis/cnxn)[CNXN Fundamental Analysis](https://www.validea.com/factor-report/cnxn)**MONEYLION INC ([ML](https://www.nasdaq.com/market-activity/stocks/ML)))** is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**MoneyLion Inc. is a financial technology company. The Company designs and offers modern personal finance products, tools and features and curates money-related content that delivers actionable insights and guidance to its users. Through its Consumer platform, accessible through the free-to-download MoneyLion mobile application and online at www.moneylion.com, it offers its integrated core suite of financial products and services to make banking, borrowing and investing accessible to everyone. Its financial products and services include RoarMoney, Instacash, Membership Programs, MoneyLion Investing, MoneyLion Crypto and Round Ups. Its marketplace solutions provide valuable distribution, acquisition, growth and monetization channels for its partners. MoneyLion Investing is an online investment account that offers access to separately managed accounts invested based on model exchange-traded fund (ETF) portfolios. MoneyLion Crypto is an online cryptocurrency account.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & PASS \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & FAIL \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of MONEYLION INC [ML Guru Analysis](https://www.validea.com/guru-analysis/ml)[ML Fundamental Analysis](https://www.validea.com/factor-report/ml)**CELLEBRITE DI LTD ([CLBT](https://www.nasdaq.com/market-activity/stocks/CLBT)))** is a mid-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**Cellebrite DI Ltd is an Israel-based software developer. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Platform enables users to collect, view, analyse and manage digital data throughout the entire investigation cycle. The Company's platform improves the investigation process for public defenders, police departments, state departments, armed services, legal and corporate security; this leads to an accelerated speed of investigations and increased crime clearance rates.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & PASS \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & FAIL \\ \hline R&D AS A PERCENTAGE OF SALES: & FAIL \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline INVENTORY TO SALES: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of CELLEBRITE DI LTD [CLBT Guru Analysis](https://www.validea.com/guru-analysis/clbt)[CLBT Fundamental Analysis](https://www.validea.com/factor-report/clbt)**AVEPOINT INC ([AVPT](https://www.nasdaq.com/market-activity/stocks/AVPT)))** is a small-cap growth stock in the Software & Programming industry. The rating according to our strategy based on Motley Fool is 63% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest. **Company Description:**AvePoint, Inc. provides a cloud-native software platform that organizations rely on to optimize information technology (IT) operations, manage critical data and secure the digital workplace. The Company's AvePoint Confidence Platform delivers a set of software-as-a-service (SaaS) solutions, empowering users in a variety of technology roles, including IT operations, development operations and cybersecurity to monitor and secure the digital workplace. Built on top of platform-as-a-service (PaaS) architecture, the AvePoint Confidence Platform offers modularity and combines cloud services architecture with industry-specific functionality to address operational challenges and the ongoing management of data, as organizations leverage a variety of third-party cloud vendors. The AvePoint Confidence Platform, and the applications that it powers, is organized into three interconnected suites of functionality, which include The Control Suite, The Resilience Suite and The Modernization Suite.The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria. \begin{table}{|c|c|} \hline PROFIT MARGIN: & FAIL \\ \hline RELATIVE STRENGTH: & PASS \\ \hline COMPARE SALES AND EPS GROWTH TO THE SAME PERIOD LAST YEAR: & FAIL \\ \hline INSIDER HOLDINGS: & PASS \\ \hline CASH FLOW FROM OPERATIONS: & FAIL \\ \hline PROFIT MARGIN CONSISTENCY: & PASS \\ \hline R&D AS A PERCENTAGE OF SALES: & FAIL \\ \hline CASH AND CASH EQUIVALENTS: & PASS \\ \hline ACCOUNTS RECEIVABLE TO SALES: & PASS \\ \hline LONG TERM DEBT/EQUITY RATIO: & PASS \\ \hline "THE FOOL RATIO" (P/E TO GROWTH): & FAIL \\ \hline AVERAGE SHARES OUTSTANDING: & PASS \\ \hline SALES: & PASS \\ \hline DAILY DOLLAR VOLUME: & PASS \\ \hline PRICE: & PASS \\ \hline INCOME TAX PERCENTAGE: & FAIL \\ \hline \end{table} Detailed Analysis of AVEPOINT INC [AVPT Guru Analysis](https://www.validea.com/guru-analysis/avpt)[AVPT Fundamental Analysis](https://www.validea.com/factor-report/avpt)[Motley Fool Portfolio](https://www.validea.com/motley-fool)**About Motley Fool**: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services. **About Validea**: Validea is an [investment research](https://www.nasdaq.com/market-activity) service that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, [click here](http://www.validea.com/) | Validea's Top Information Technology Stocks Based On Motley Fool - 8/4/2024 | News | Validea | John Reese | 0.0552 | 8.12324 | 7.89124 | 7.78723 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.20384 | 7.15723 | 7.30844 | 8.39545 | 7.31874 | 7.31668 | 7.64515 |
Subsets and Splits